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ABSTRACT 
            
 The role of autoreactive, antigen-specific T-cells in the development of 
autoimmunity has long been documented. T-cells expressing chimeric receptors are 
specifically redirected against such cells and have been proven to suppress autoimmune 
encephalomyelitis, the murine model of multiple sclerosis. We here demonstrate the 
ability of humanized chimeric receptors to suppress experimental autoimmune 
encephalomyelitis (EAE) in a humanized mouse model by redirecting T lymphocytes 
against autoreactive T-cells. The receptors were synthesized by linking the 84-102 
epitope of human myelin basic protein (MBP) to the extracellular and transmembrane 
domains of the beta chain of human major histocompatibility complex (MHC) class II 
molecule and the cytoplasmic zeta chain of T cell receptor and pairing it to the alpha 
chain linked to zeta. CD8+ receptor-modified T-cells (RMTC) were able to recognize the 
cognate TCR receptor of antigen-specific cells and induce cytokine secretion, 
proliferation, and cytolysis upon engagement. Most importantly, the RMTC were able to 
specifically kill antigen-specific cells both in vitro and in vivo and prevent EAE disease. 
We hypothesize that the humanized chimeric receptors could be used as a therapeutic 
approach for multiple sclerosis in the future. 
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Chapter 1. General introduction 
 
1.1 Historical perspective of multiple sclerosis 
        In 1868, the French neurologist Jean-Martin Charcot examined a young 
woman who exhibited a new type of tremor, abnormal eye movements and slurred 
speech. On autopsy, she was found to have central nervous system (CNS) “plaques” that 
we now associate with multiple sclerosis (MS). Charcot named the disease “sclérose en 
plaques”. By the end of the 19th century, the major symptoms of MS were well-
characterized and a new era of neurology arose.  
Multiple sclerosis is a chronic progressive demyelinating disorder of the white 
matter of CNS characterized by loss of myelin with relative preservation of axons. It is 
the most common CNS autoimmune disease, affecting approximately 1 million people 
worldwide (250,000 in the United States) (2). The disease disproportionately affects 
females at a 2:1 sex ratio, has no single defined cause, and several genetic markers are 
associated with susceptibility. 
Genes and environment play a major role in the pathology of MS. Among the 
primary genetic associations, human leukocyte antigen (HLA) class II genes on 
chromosome 6 and particularly HLA-DRB1 (HLA-DRB1*1501 and DQB1*0602) were 
found to increase the risk for MS (3). The risk of disease in a monozygotic twin of an 
affected individual is far greater than in dizygotic ones (25-30% compared to 2-5%). 
Also, the risk that first-degree relatives of patients with MS will get the same disease at 
some point in life is seven times higher than for the general population (4). These 
findings suggest a very strong genetic component (although not a Mendelian one). 
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Epidemiological studies implicated geography as another factor for MS. Studies 
have shown that the disease is more prevalent in the temperate regions and western 
hemisphere (Germany, Scandinavia, Canada, northern US) and that migration from a 
high-incidence area to a low incidence one before puberty significantly decreases the risk 
of acquiring MS later in life (5). Therefore, environmental factors seemingly more 
prevalent in temperate regions combine with genetic factors to determine MS 
susceptibility. 
 
1.2 Clinical signs and symptoms of MS 
MS can exhibit a very large range of signs and symptoms commonly first seen in 
the third to the fourth decade of life. 85% of patients have the typical relapsing-remitting 
multiple sclerosis (RRMS), with episodes triggered by viral infections followed by 
remissions with no residual damage or different cumulative amounts of chronic 
impairment. Over time, approximately 30% of these patients will undergo transformation 
to a secondary progressive form with less frequent acute attacks, but with gradual 
worsening of symptoms and permanent disabilities. A subset of RRF is benign MS, with 
few and mild attacks and a limited disease course or total recovery. Ten percent of 
patients with MS develop progressive deterioration of neurological functions without 
relapses and a more aggressive form of disease, called primary progressive MS (PPMS) 
(6). 
Symptoms displayed by MS patients vary according to the location of lesions. 
Cerebellar and cerebral plaques typically accompany speech and balance problems, 
tremors and loss of coordination. Motor and sensory nerve tracts deficits are revealed by 
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spastic paralysis, muscle weakness, diplopia and other visual problems including 
blindness, urinary and bowel problems, and tingling, numbness, and loss of touch and 
pain. Patients may also show signs of depression, cognitive and emotional problems, 
fatigue, and sexual disturbances.  
 
1.3 Diagnosis of MS 
MS is not easy to diagnose. There is no single test adequate for diagnosis. 
Physicians rely on history, clinical signs and symptoms, and various tests including 
magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, serology, and 
sensory evoked potential testing. The classic approach is manifestation of at least two 
clinical signs along with MRI lesions localized in the brain or spinal cord which confirm 
the diagnosis. MRI with gadolinium contrast shows enhancement of lesions that correlate 
with perivascular inflammation. Almost 90% of MS patients will show oligoclonal 
immunoglobulin (Ig) G in CSF. Although this finding is not specific for MS and can only 
be considered suggestive, it is very useful in ruling out infectious diseases or tumors that 
might mimic this autoimmune disease. Optic nerve lesions that might not show up on 
MRI can be detected by visual evoked potentials, which will reveal prolonged latencies 
consistent with plaques located within optic pathways. Serology is also not specifically a 
useful tool in diagnosing MS, but it proves helpful in differential diagnosis with other 
entities (7).  
At the microscopic level, MS plaques reveal changes located primarily at the level 
of optic nerves, chiasm, tracts, brainstem, spinal cord, and cerebellum, consisting of 
perivascular edema and an inflammatory infiltrate of T lymphocytes and macrophages.  
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Myelin is stripped from the axons impairing saltatory conduction and causing conduction 
block (Figure 1-1). Axons tend to be spared (8). During periods of remission, 
inflammation and edema subside and axons can undergo remyelination and carry out the 
normal function again. Repair of damaged areas occurs more completely in early stage 
disease when oligodendrocytes are still able to build a new myelin sheath; in time, as the 
disease progresses more advanced lesions develop characterized by gliosis. This creates a 
boundary between myelin producing cells and axons, therefore rendering remyelination 
inefficient.  
 
1.4 Pathobiology of MS 
There is no clear proof of the cause of MS. Epidemiological evidence from 
genetics, geography, and socio-economic factors has led many to hypothesize that there is 
a viral etiology (9). A definite pathogen has not been identified, though some microbes 
bear similar structures with self-antigens in the CNS such as myelin basic protein (MBP), 
myelin oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP) and it is 
possible that these promote autoimmunity through the mechanism of molecular mimicry. 
Molecular mimicry is the process by which a viral or bacterial infection causes activation 
of T-cells that are cross-reactive with self antigens. It is still a major mechanism for 
triggering autoimmune diseases (8). 
There are other hypotheses for the etiology of MS including bystander activation 
and superantigenic T cell activation. In the bystander activation hypothesis, T 
lymphocytes are activated in the periphery by infectious agents presented on the surface 
of antigen presenting cells (APCs) and become capable of crossing the blood brain
 5 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. H&E staining of perivascular infiltrate in active MS plaque (top) and 
Prussian-blue staining of a MS plaque (bottom). Source:  
http://www.neuropathologyweb.org/chapter6/chapter6aMS.html (10). Accessed on 
January 21, 2007. 
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barrier (BBB). The cells which develop into activated T-cells are CD4+ or so-called T 
helper cells type 1 (Th1). Although both Th1 and Th2 cells are present in MS, Th1 cells 
are able to secrete proinflammatory cytokines and also express a high level of adhesion 
molecules such as intercellular adhesion molecules (ICAM) or vascular cell adhesion 
molecule (VCAM). Inflammation upregulates adhesion molecule expression on the 
endothelium of the BBB, thus making it more permeable for penetration. Th1 cells also 
secrete matrix metalloproteinases that further compromise the integrity of the BBB (11). 
The opening of this natural barricade enables future inflammatory cells to penetrate into 
the CNS. 
Once within the CNS, activated Th1 cells will die or be eliminated unless 
restimulated. An autoantigen or again, a microbe presented on the surface of CNS APCs 
(microglia) may restimulate and promote the expansion of T-cells, and induce the release 
of proinflammatory cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor-α 
(TNF-α)  that lead to macrophage activation. These cells release neurotoxic components 
(nitric oxide, reactive oxygen species) that damage the myelin sheath causing the 
structural and functional damage that results in MS (Figure 1-2). 
In addition to this indirect means of tissue damage, infectious agents can directly 
damage tissues through recruitment of T-cells with new specificities, including 
autoaggressive T-cells to the CNS. In a process called epitope spread, the immune 
response can switch from being initially restricted to a microbial antigen to incorporate 
an added self antigen-specific response. Thereby, a secondary autoimmune reaction can 
develop (12).  
Activation of T-cells by superantigens has also been proposed as a trigger for MS.  
 7 
 
 
 
 
 
Figure 1-2. Immunopathogenesis of the MS lesion. APC = antigen presenting cell; 
IFN = interferon; IL = interleukin; Mic = microglia; MMP = matrix metalloproteinase; 
MO = monocyte; NAA = nacetylaspartate; NO = nitric oxide; Pl = plasma; 
VCAM = vascular cell adhesion molecule. Adapted and reprinted with permission – 
Suhayl Dhib-Jalbut et al. 2006. Neurodegeneration and neuroprotection in multiple 
sclerosis and other neurodegenerative diseases. Journal of Neuroscience 176:198-215. 
 
 
 
 
 
 
 
 
 8 
According to this theory, virus and bacteria superantigen is able to cross-link the T-cell 
independent of peptide antigen, thus activating T-cells that can either expand or be 
deleted. Since superantigens preferentially recognize particular Vβ families, a large 
proportion of T-cells might be activated during this process. As not all self-reactive T-
cells are eliminated in the thymus by negative selection, myelin-specific ones can become 
activated and trigger an autoimmune response (13). Similar to the epitope spread theory, 
superantigen-mediated stimulation of autoreactive T-cells is detectable in mouse model 
but there is no direct evidence for this in MS.  
For many years, Th1 CD4+ autoreactive T-cells have been incriminated as the 
major T cell offenders in MS. This theory has more recently been challenged by the 
recognition of  a new subset of autoaggressive T-cells, CD4+Th-17+, whose 
differentiation is promoted by APCs in the presence of interleukin (IL)-6 and 
transforming growth factor-beta (TGF-β) and whose expansion requires IL-23 (14). 
Studies show that Th17 cells secrete proinflammatory cytokines (IL-17, IL-6, TNF-α), 
but not IFN-γ and IL-4 and adoptive transfer of these cells can induce severe 
experimental allergic encephalomyelitis (EAE) disease (15). In models of MS and other 
autoimmune diseases, disease can be suppressed by blockade of IL-23 pathway or the 
downstream IL-17 and IL-6 factors (16).  
CD8+ T-cells are also incriminated for causing an immune attack by recruitment 
and clonal expansion within the CNS. They can recognize peptides presented by major 
histocompatibility complex (MHC) class I-expressing brain cells and even outnumber 
CD4+ T-cells in the inflammatory infiltrate that characterize MS. Little is known about 
the role of CD8 cells in the pathology of MS in regards to the several aspects, such as 
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means of CNS invasion, proliferation, apoptosis, and further clarifications are required 
(17). The invading cytotoxic T lymphocytes release pro-inflammatory cytokines, such as 
IFN-γ and TNF-α, thus inducing expression of MHC class I molecules in the brain in 
vitro (18). 
It is clear that the above theories on the cause of MS are demonstrable in the 
mouse models but will be difficult to verify in humans. They leave many questions and 
lots of alternatives. 
 
1.5 Animal models of MS 
Modeling MS is a challenging task. The disease is complex and little is known 
about its triggers and mechanisms. 
 The first attempt to build an animal model of this disease was in the early 1930s 
when Rivers and collaborators noticed that certain infections (measles, smallpox) were 
followed by a wide range of CNS symptoms. Biopsy of these patients’ brains revealed a 
perivascular demyelinating inflammatory infiltrate that characterized the acute 
disseminated encephalomyelitis. This group tried to reproduce the disease in monkeys by 
repeated intramuscular injections of extracts and emulsions of rabbit brain. Although the 
model did not accurately reproduce the human disease, it was still considered to be a 
groundbreaking discovery (19). A decade later, Kabat adjusted the disease-induction 
procedure by using an adjuvant to increase the immune response (20). This had two 
major consequences: it made the immunization protocol more manageable since the 
animals, unlike Rivers’ model, only needed one injection, and it incriminated myelin as 
the culprit for MS since only animals injected with adult rabbit or monkey brain plus 
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adjuvant got sick but not those injected with rabbit lung or fetal rabbit brain.  
In 1960s and 1970s the concept of EAE developed as adoptive transfer of 
splenocytes from rats immunized with spinal cord extract into normal recipients was 
shown to induce disease (21). 
 
1.5.1 Current animal models of MS 
EAE is considered to be primarily mediated by MHC II-restricted CD4+ Th1 cells 
that secrete proinflammatory cytokines such as tumor TNF-α and IFN-γ (22). EAE can be 
induced in susceptible strains of small, easy-to-handle animals such as mice, guinea pigs, 
and rats by active immunization with myelin antigens including MBP, PLP, MOG, and 
others, plus complete Freund’s adjuvant (CFA). The administration of Bordetella 
pertussis toxin (PTx) increases the permeability of the BBB, thus creating a “breach” for 
activated T-cells that enter the CNS and cause the local inflammation (23). The first signs 
of neurological disease can be detected as early as ten days post immunization and 
depending on the model system may resemble the human relapsing-remitting or 
progressive disease forms. Inbred mice are most commonly used as the animal model for 
EAE due to their small size and well-defined genetics. Typically, disease is scored on a 1 
to 5 scale (24) and the animals are euthanized at a score of 4 or 5 according to the ethical 
guidelines (Table 1-1).  
 Not all strains of mice exhibit the same disease course and symptoms when 
immunized with myelin antigens. While a certain strain of mice might be susceptible to a 
peptide antigen, another one could be resistant to the same antigen. There are now clear 
“recipes” for EAE induction in different mouse strains (25). Some of the standard 
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Table 1-1. Clinical EAE scores. 
 
  Disease score Clinical signs of disease 
 
0                                              No signs of disease 
1 Limp tail 
  2    Partial hind leg paralysis 
  3    Complete hind leg paralysis 
  4    Hind and front leg paralysis 
  5    Moribund or dead 
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protocols include relapsing-remitting EAE in SJL mice immunized with PLP139-151, MBP-
induced EAE in PL/J or B10.PL mice, or MOG35-55-induced EAE in C57BL/6 mice. The 
disease is mostly T cell-mediated. However, MOG not only induces a T cell response, but 
also production of demyelinating autoantibodies (26). MOG-specific T-cells and 
autoantibodies were also found in circulation in patients with MS (27), but the cause that 
triggers their activation is still unknown. 
 
1.5.2 Adoptive transfer EAE 
The discovery that adoptive transfer of myelin-specific T-cells can induce EAE in 
naïve syngeneic recipients validated the autoimmune nature of EAE in mice (28). 
Susceptible mice are immunized with a particular antigenic peptide followed by isolation 
of T-cells from draining lymph nodes and spleens, and in vitro stimulation of the T-cells 
with the myelin peptide. The T-cells are then injected into naïve recipients who develop 
disease. This approach showed that the CNS can be invaded by activated 
encephalitogenic T cell clones that are capable of crossing the BBB and emphasized the 
autoimmune nature of the phenomenon. The encephalitogenic cells were thought to bear 
a CD4+Th1 cell phenotype and recognize self peptides presented in the context of MHC 
class II molecules. Later data showed that the MOG35-55 epitope is able to activate CD8+ 
MOG-specific αβ T cell receptor (TCR) positive cells that can be adoptively transferred 
into naïve C57BL/6 recipients, causing a much more severe clinical disease sustained by 
more destructive histopathologic CNS lesions. Furthermore, these antigen-specific cells 
were capable of surviving in vivo as shown by their ability to be retrieved from recipient 
mice (29). A role for CD8+ T-cells in murine EAE has been controversial and not 
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uniformly supported. 
  Although EAE induction seems fairly straightforward if following the rule “right 
strain-right antigenic peptide”, one must not overlook the association between the antigen 
and its corresponding MHC. T-cells cannot recognize an antigenic peptide properly 
unless it is presented on the right MHC. Beta2-microglobulin knockout (β2m-/-) mice 
lacking MHC class I  are resistant to EAE induced by adoptive transfer of CD8+ MOG-
specific TCR+ cells (29). Likewise, CIITA mice lacking MHC class II, as well as mice 
deficient for invariant chain (Ii) and H-2M (DM) are resistant to both direct priming with 
peptide and adoptive transfer of CD4+ peptide-specific T-cells. Interestingly, APCs from 
these knockout (KO) mice can present MOG peptide to CD4+ T-cells, but they are not 
capable of presenting and processing the myelin protein, thus rendering the mice resistant 
to EAE induction. The fact that MOG EAE cannot be induced in class II deficient mice 
but can in β2m-/- mice argues against a significant role for MOG-specific CD8+ T-cells 
(30). 
 
1.5.3 Transgenic mice as models for MS 
Key to understanding human autoimmune diseases is to dissect the mechanisms 
of tolerance induction. The challenge for MS is to discover how seemingly tolerant self-
reactive cells in the periphery become activated, are able to penetrate the CNS, and 
mediate disease. B10.PL mice were engineered to express a transgenic α2+ and Vβ8.2+ 
TCR specific for MBP epitope 1-11. These mice were highly susceptible to MBP-
induced EAE and some even developed spontaneous disease. T-cells removed from 
spleens or lymph nodes of these animals proliferated and secreted cytokines in response 
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to in vitro MBP stimulation (31). This MBP-specific transgenic mouse model has 
provided not only a unique model to study MS but also important information concerning 
the failure of the thymus to delete the antigen-specific T-cells, the mechanisms of 
peripheral tolerance, and the circumstances in which autoreactive, antigen-specific cells 
can cross the BBB and cause inflammation and myelin destruction (32). 
Recently, another animal model has been developed that has proved extremely 
useful in the research of demyelinating diseases: the opticospinal EAE (OSE) mouse. A 
transgenic mouse expressing a TCR specific for MOG 35-55 (denoted TCRMOG) was 
crossed with a MOG-specific Ig heavy-chain knock-in mouse (denoted IgHMOG) both on 
a C57BL/6 background. The latter mouse had B cells producing antibodies against MOG. 
Single-transgenic mice did not undergo spontaneous EAE disease, but the double-
transgenic animals exhibited signs of an EAE-like disease, closer to the human Devic 
disease than to MS. Devic disease differs from MS only in regards to the site of the 
primary attack (spinal cord and optic tracts instead of the brain) and more frequent and 
severe attacks compared to MS. Nevertheless, mice exhibited a pathologic finding similar 
to what is seen in MS: inflammatory infiltrate with prevalence of CD4+T-cells and 
macrophage, demyelination, and sometimes axonal loss. Since single-transgenic mice did 
not develop spontaneous disease, one can infer that interaction between MOG-specific T 
and B cells present in the double-transgenic mice is responsible for development of 
disease. Although OSE mice do not reproduce the classical MS, they still are extremely 
valuable for the understanding of the role of B cells in the pathogenesis of EAE since 
MOG-specific B lymphocytes do not only act as APCs but also proficiently capture even 
smallest amounts of peptide, process it, and present it to T-cells (33). 
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1.6 Therapeutic approaches for MS 
The concept that MS is a non treatable disease has changed dramatically over 
time. There is currently no definitive cure, but long-term survival has increased in recent 
years due to new discoveries about the pathology of the disease, better and earlier 
diagnostics including MRI, and better clinical trial designs. While some therapies have 
been successfully introduced and have shown to improve symptoms, others, having been 
proven to work in animal models, have not shown any benefit or even worsened the 
disease course in humans. Nonetheless, efforts are increasingly centered towards making 
MS a much more manageable disease than in the past. 
There are two goals to therapy: the first one is to treat disease symptoms, such as 
spasticity, vertigo, depression, bladder and bowel dysfunctions. The second one targets 
the pathogenic cascade: peripheral activation of antigen-specific T-cells, penetration of 
BBB and activation and proliferation in the CNS, demyelination, and interaction of TCR 
with peptides loaded on MHC complexes.  
 
1.6.1 Glucocorticoids 
Corticosteroids have long been considered a panacea for autoimmune conditions, 
and MS is no exception to the rule. Studies with intravenous (iv) methylprednisolone 
showed improvement of symptoms in patients with chronic progressive disease as well as 
acute relapses (34). Steroids have also proved beneficial for optic neuritis which is often 
the first clinical manifestation of MS (35). Therapeutic use of corticosteroids nevertheless 
has more recently decreased, partly due to their side effects (osteoporosis, glaucoma, 
worsened diabetes, suppression of adrenal glands, etc.), and partly due to the advent of 
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new therapies. However, they are still important tools though in treating RRF of MS and 
secondary progressive MS. 
 
1.6.2 Cytokines 
Interferon beta (IFN-β) 1a and 1b acts through a mechanism that is not fully 
understood, but it is proposed to involve a drop in IFN-γ levels, blockade of myelin 
attack, inhibition of metalloproteinases, and various modulatory effects on chemokine 
and adhesion molecule production (36). Several drugs currently on the market (Avonex, 
Rebif, Betaseron) were shown to reduce the annualized relapse rate by approximately 
one-third. A new study revealed a decreased concentration of monocyte-derived non-
classical MHC molecule (class Ib) called HLA-G in patients with MS. This molecule is 
important since it inhibits both Th1 and Th2 cytokine production (IFN-γ, IL-2, and IL-10 
respectively) by CD4+ T-cells. HLA-G levels were increased to almost normal levels 
after treatment with IFN-β (37).  
TNF-α or cachectin has already been shown to be an important mediator in the 
pathology of MS due to its ability to mediate inflammatory responses. However, its 
therapeutic blockade in MS has been very controversial. Studies have shown that TNF-α 
is increased in the CSF of patients with MS in direct correlation to the severity of the 
disease and neurological impairment (38). However, results of anti-TNF-α therapy with 
TNF-receptor fusion proteins such as etanercept (Enbrel) or monoclonal antibodies such 
as infliximab (Remicade) have been disappointing. Disease course was worsened and 
there was actually a new case of MS reported (39). Data of TNF blockade in EAE has 
yielded confusing results. Treatment of adoptive transfer EAE with soluble TNF 
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receptors reversed the disease and protected against recurrent episodes (40). In contrast, 
complete deletion of the gene in TNF knockout mice led to high mortality and severe 
neurological defects. Moreover, treatment with recombinant TNF reduced the disease 
course and even prevented progression of EAE (41).  
IL-10 and TGF-β2 are suppressive cytokines in EAE. IL-10 is produced by 
regulatory CD4+ cells and selectively upregulated during recovery in EAE model. Just 
like TNF-α, studies of IL-10 treatment of EAE were mixed, particularly because the route 
of administration seemed to play an important role. Intravenous injections exacerbated 
the disease (42), whereas intranasal immunizations partially inhibited EAE (43). TGF-β2 
has not been approved for the therapy of MS due to the nephrotoxic effects seen in mice.  
 
1.6.3 Antigen-derived immunotherapies 
As corticosteroids and other drugs impair the general immune defense by 
eliminating or suppressing not only the disease-causing cells, but other T-cells, it has 
become imperative that therapeutic approaches specifically target antigen-specific cells. 
A major limitation in the therapy of MS is the phenomenon of epitope spread. This 
develops after the initiating event when CNS provides the proper environment for 
reactivation of T-cells (self-antigens and MHC complex and co-stimulatory signals 
necessary for reactivation), thus recruiting and stimulating cells reactive not only against 
the initial causative antigen, but also against other neighboring self-peptides. This leads 
to a more extensive repertoire of immune responses that may amplify tissue destruction. 
A major goal of antigen-derived therapies is to circumvent this problem by mediating 
bystander suppression. For example, self-reactive antigen-specific Th2 or Th3 cells that 
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were initially generated by oral tolerization of mice and are capable of secreting anti-
inflammatory cytokines (IL-4, IL-10) may globally downregulate the immune response 
after activation (44). One method to generate these regulatory T-cells is through peptide 
tolerization. Two approaches to tolerization with peptides have been extensively studied: 
altered peptide ligands (APL) and mucosal administration of antigen.   
 
1.6.4 Altered peptide ligands  
It is well known that activation of CD4+ Th1 cells depend on the interaction of 
immunogenic peptide bound to MHC class II with the TCR along with a costimulatory 
signal from APCs. Activation leads to proliferation, cytokine production, and cytolysis. 
Lack of costimulation renders the cells anergic to subsequent antigenic stimulation. Past 
studies have shown that an immunogenic peptide that has some of its residues mutated 
can stimulate Th1 and Th2 cells to fulfill some functions, but not proliferation. This 
phenomenon is called partial activation. The basic principle is that the surface expression 
of important molecules, such as CD3 did not change, nor did the MHC binding residues 
in the peptide. The only residues that were changed were the TCR binding moieties. 
When the cells were cultured with the original peptide and APCs, the T-cells proliferated 
normally. When the cells were first stimulated with the mutated peptide, upon subsequent 
stimulation with the original peptide, T-cells were rendered unresponsive to the 
immunogenic peptide (45).  
APLs were also approached in the therapy of EAE induced by adoptive transfer of 
a pathogenic T cell clone specific for MBP epitope p87-99. This clone caused a 
heterogenous inflammatory infiltrate of the CNS that disappeared when the clone was 
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tolerized in vivo with an analogue of the immunogenic peptide that carried a 
phenylalanine to alanine substitution at position 96. Direct transfer of the same clone 
treated with the APL led to prevention of EAE and even reversion of paralysis. The 
mechanism of action is still unclear since the therapeutic APL has no influence on 
proliferation of pathogenic T cell clone to the immunogenic peptide MBP 87-99, so there 
is no MHC competition or TCR antagonism. It has though, been noticed that deletion of 
the inflammatory infiltrate by APL depends on the availability of IL-4. Treatment with 
APL promoted a shift in the ratio between IL-4 and TNF-α  to an increase in the former 
which downregulates the latter (46). Even though treatment of EAE with APL showed 
encouraging results, this approach in human MS has led to a controversial outcome, as 
some trials ending in exacerbations of disease (47). 
 
1.6.5 Synthetic copolymers 
Glatiramer acetate (Copaxone) consists of a mixture of alanine, glutamic acid, 
lysine, and tyrosine that acts like a universal antigen, “luring” autoreactive T-cells (48). It 
efficiently binds to MHC class II molecules (DR, but not DQ or class I), thus hindering 
self-peptide from binding in the same groove. It is not fully understood how the drug 
works: it was initially thought to cross-react with MBP peptide and then compete for 
MHC binding, but has also been found to induce regulatory T-cells (49). Since 
Glatiramer-activated, Th2-like cells can cross the BBB, they enter the CNS and secrete 
anti-inflammatory cytokines, such as IL-4, IL-10, IL-6, thus promoting a non-
inflammatory environment. These Glatiramer-activated cells also exert a neurotrophic 
effect by producing brain-derived neurotrophic factor (BDNF) (50). Copaxone can 
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successfully prevent EAE induced by several peptides (MBP, PLP, or MOG) and phase 
III clinical trials have also shown it to be beneficial in RRMS (51).  
 
1.6.6 Mucosal administration of antigen 
Oral or nasal administration of antigens responsible for MS and EAE has yielded 
controversial results. Self-specific T-cells can be activated within six hours of oral 
administration of peptide and consecutive administration of the same peptide will 
decrease the number of effector T-cells. The route of administration is important, with the 
intranasal one seemingly more efficient than oral (“nasal” versus “oral tolerance”). 
Peptide administered intranasally seems to be able to reach the thymus where it can 
mediate apoptosis of high affinity thymocytes as opposed to the oral route of 
administration where the antigenic peptide might be destroyed by the acid in the 
gastrointestinal tract. The mechanisms governing mucosal tolerance - anergy or deletion 
of antigen-specific T-cells - are not clear.  Although feeding the inducing peptide 
at time of disease induction prevented EAE in mice and generated enthusiasm regarding 
the therapeutic outcome of the human disease (37),  this approach failed in MS clinical 
trials (52).  
 
1.6.7 T-cell vaccination  
Antigen-stimulated T-cells can induce EAE equally as well as the antigenic 
peptide itself in adjuvant. T-cell vaccination (TCV) uses irradiated, activated antigen-
specific CD4+ T-cells to “vaccinate” mice without causing EAE similar to microbial 
vaccination against infectious agents. These cells induce CD8+ T-cells capable of killing 
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the autoreactive CD4+ T-cells as well as preventing antigen-induced proliferation of the 
vaccine T-cells themselves. Pilot trials in MS patients have used TCV with MBP-reactive 
T-cells isolated from their blood, activated in vitro and irradiated to abrogate subsequent 
proliferation. These clones were then injected back into the patients, resulting in the 
specific deletion of circulatory MBP-specific T-cells (53). Although this procedure has 
not been used to treat patients on a large scale, it is still considered for future evaluation. 
 
1.6.8 Monoclonal antibodies  
Activated T-cells express high levels of surface adhesion molecules like VCAM 
or ICAM and upregulate their receptors on the endothelium of the BBB, thus enabling T-
cells to cross the BBB and cause inflammation in the CNS. Antibodies directed against 
the ligand-receptor pair could potentially block this first step in the CNS homing of T-
cells. VCAM-1 expression is low on blood vessels under homeostatic conditions; 
however, expression is increased under conditions of inflammation, such as found in 
brain tissue of EAE-induced animals and human MS. Administration of antibody against 
α4β1-integrin prevents accumulation of leukocytes in the brain and subsequent 
development of EAE (54). The monoclonal antibody anti-α4β1-integrin was named 
Natalizumab and has been licensed for clinical use (55). 
 
1.6.9 Gene therapy in MS 
Gene therapy for autoimmune disease has emerged as a result of progress in 
deciphering in greater detail the pathologic mechanisms by which self-antigens mediate 
autoimmune diseases. This approach can be very specific and aims to deliver a gene or 
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gene product that can specifically block disease. Gene therapies may be antigen-specific, 
while hopefully avoiding the general suppression of the immune system associated with 
conventional treatments. The goal of gene therapy in MS is generally to deliver immune-
modulating molecules (blocking antibodies, anti-inflammatory cytokines, etc.) by 
different means such that antigen-specific immune tolerance can be achieved. 
 One new tactic is the delivery of anti-inflammatory cytokine genes (IL-4, IL-10, 
or IL-12 p40 subunit) by viral vectors that are administered intrathecally in order to 
directly concentrate the gene product in the CNS, slowly releasing the cytokine of 
interest. Different vectors may be used: non-replicative herpes simplex virus type 1(HSV-
1), retroviruses or adenoviruses are able to accommodate the genes and infect cells. 
Potentially, EAE could be both prevented and treated using an HSV-IL-4 system by 
downregulating proinflammatory cytokines and therefore, macrophage activation and 
CNS invasion (56).  
An even more practical way of delivering anti-inflammatory cytokines by means 
of viruses is to retrovirally transduce antigen-specific CD4+ T-cells. The autoreactive T- 
cells will migrate to the CNS and therefore, provide a “home delivery” of Th2 regulatory 
 cytokines to the autoimmune lesions (57).  
Receptor-modified T-cells (RMTC) have emerged in the past five years as a 
means to redirect T-cells against antigen-specific T-cells and have already proven useful 
in infectious diseases and cancer. In this case new, often chimeric, signaling receptors are 
expressed on T lymphocytes. The benefit of using T-cells is their effector and regulatory 
functions, their ability to grow well in vitro and traffic to most sites of the body. Chimeric 
receptors containing extracellular domains from MHC class I linked to a signaling 
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domain from TCR can be retrovirally transduced in T-cells or T-cell hybridoma. Upon 
encounter and recognition of their cognate TCRs, these chimeric receptors exhibit 
effector functions such as cytokine secretion, proliferation, or cytolysis depending on the 
type of T cell in which they are transduced (CD4+ or CD8+) (58).  
 A more specific surrogate receptor able to target autoreactive, encephalitogenic 
Th1 cells has recently been designed. This chimeric receptor contains the extracellular 
and transmembrane domains of mouse MHC class II I-A β and α, the zeta cytoplasmic 
signaling domain, and also an antigenic peptide, MBP89-101, linked on its surface. This 
receptor not only recognizes the cognate TCR but can also be stimulated as a result of 
this interaction. Among outcomes of this TCR-TCR interaction, CD8+ T-cells transduced 
with retrovirus containing this construct can specifically kill CD4+Th1 antigen-specific 
T-cells. Although the chimeric receptor was designed to only carry one peptide epitope, 
experimental results show that this approach could also address the main problem of 
EAE, epitope spread, even when RMTC are administered one month after disease 
induction (59). One benefit of this approach is that it does not interfere with the whole 
immune system, but selectively targets encephalitogenic, antigen-specific cells. 
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Chapter 2. Development of chimeric receptors 
 
Chimeric receptors (CRs) are hybrid combinations of a recognition domain 
(variable regions of an Ig or a MHC molecule) and a signaling domain (TCR moieties 
responsible for signal transduction). The name “chimeric” resides in their mixed 
structure: CRs carry a recognition domain containing variable regions in charge of 
antigen recognition and an intracytoplasmic domain responsible for signal transduction 
(60) (Figure 2-1).  
For a better understading of how CRs were engineered, I will briefly discuss the 
structure of IgG and TCR. 
IgG is composed of two identical heavy and two light chains (kappa or lambda). 
The light chain has a variable region and a constant one and the heavy chain has 
additionally two or three constant domains. The chains are kept together by disulfide 
bonds. When treated with papain, the Ig breaks into two equal fragments of 45-50 KDa 
called fragments of antigen binding (Fab) and a third fragment of 50 KDa called 
crystalizable fraction (Fc). The antigen binding site consists of the variable domains of 
the light and heavy chains.  
 TCR is also composed of two chains, alpha and beta, each of which has a variable 
and a constant region. Its role is to recognize antigen-MHC complexes. The signals 
triggered by antigen recognition are not transduced by the TCR but by two proteins, CD3 
and zeta (ζ), that are noncovalently linked to TCR, forming the TCR complex. Upon 
recognition of peptide, a cascade of signals including tyrosine phosphorylation and 
activation of nuclear factor-kappa (NF-κB), nuclear factor of activated T-cells (NFAT), 
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Figure 2-1. Structure of the T-cell receptor and a chimeric receptor. Reprinted with 
permission – Claudia Rössig, Malcolm K. Brenner. Chimeric T-Cell Receptors for the 
Targeting of Cancer Cells. Acta Haematol 2003;110:154-159. 
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and activating protein-1 (AP-1), is triggered, eventually leading to cell proliferation and 
differentiation. The cytoplasmic domain of CD3 and ζ contain a conserved sequence 
called immunoreceptor tyrosine-based activation motif (ITAM) that plays a crucial role 
in signaling. Upon phosphorylation, ITAMs become docking sites for a tyrosine kinase 
called ζ-associated protein of 79 kDa (ZAP-70), ultimately leading to changes in gene 
expression in the T-cells.  
 CRs represent a smart combination between the ability of TCR and B cell 
receptor (BCR) to recognize different antigens and elicit intracytoplasmic signal 
transduction events leading to different effects. Some of the earlier CRs were constructed 
by using both variable region of the heavy chain (VH) and variable region of the light 
chain (VL) combined with the α or β constant domain of the TCR (61). Eshhar engineered 
a chimeric TCR composed of the variable region domain Fv of an antibody and the 
constant region of TCR. This receptor can be expressed as a transgene in T-cells via 
retrovirus, but due to the fact that two genes (VH and VL) have to be transfected into the 
same cell by two separate retroviral vectors, the efficiency of transduction was low. 
Consequently, this problem was overcome by joining together VH and VL into a single 
chain variable region (scFV) connected by a linker peptide (62, 63). The scFv is part of 
the extramembrane portion of the construct and is responsible for antigen recognition. 
This is linked to a region consisting of the gamma (γ) or zeta cytoplasmic tail of the TCR. 
The two domains are linked by a hinge region that works as a spacer, increasing the 
distance between scFV and the plasma membrane. The hinge region belongs to IgG and 
accounts for the differences in the amino acid composition of the four classes of IgGs. It 
is placed between the Fab fragment and the constant CH2 and CH3 domains of the heavy 
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chains and determines the flexibility of the IgG molecule. Flexibility is important for 
further effector functions of the IgG such as C1q binding and complement activation 
(64); this feature and also the number of inter-heavy chain disulfide bonds in the hinge 
region is strictly characteristic and different for each IgG subclass. Different hinges were 
used, such as the hinge region of human IgG1 or CD8 or part of the extracellular region 
of CD28  some of which showing better expression in T-cells than others (65). The 
advantage of using the variable domain from Ig resides in the non-MHC restricted, 
antibody-type specificity that leads to a more ubiquitous array of specificities that can be 
transferred to T-cells through CRs.  
Similar to the classic TCR, the mere contact between T-cells bearing chimeric 
receptors and target cells does not lead to cytolysis of latter. The CR can only guarantee 
specific recognition of target, but does not confer effector function to the T-cells unless 
they are activated upon this recognition. This may require the presence of a co-
stimulatory signal and although a definite role has been established for induction of 
effector T-cells from naïve T-cells, it is not clear whether the costimulation is also 
required for the induction of effector cells from memory T-cells. The two signals theory 
states that T-cell activation requires recognition of antigen-MHC complex and 
costimulation; T-cells stimulated in the absence of costimulation are rendered tolerant 
rather than memory T-cells (66).  
CD28 is a membrane protein with well-defined ability to promote T-cell 
proliferation and differentiation and induction of cytokine secretion upon binding of B7 
molecules on APCs. The addition of the cytoplasmic domain of the co-stimulatory CD28 
molecule to the engineered zeta signaling tail improved the efficacy of CR-transduced T- 
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cells (67). Another co-stimulatory pathway is mediated by CD137 that belongs to the 
TNF family. Stimulation of CD 137 inhibits activation-induced cell death (AICD) (68). 
CRs engineered as described can be transferred into human or murine T-cells and 
redirected against microbial antigens or tumor antigens in a manner independent of MHC 
restriction. Replication-defective viral vectors are used for transduction of CRs into T- 
cells. Several different vectors have been tried for this strategy, each with advantages and 
disadvantages. Adeno-associated vectors can be easily delivered into dividing and non-
dividing cells and have high transduction efficiency. Unfortunately, they integrate at low 
frequency and gene expression is, therefore, temporally limited (69). Retroviral vectors 
are better at integrating into the target genome but the target cell must be activated to 
incorporate the retrovirus. Future concerns have been raised as to whether viral 
integration may be oncogenic. 
Pre-clinical trials using CRs for the therapy of infectious diseases have yielded 
controversial results. Human immunodeficiency virus (HIV) constitutes an example. 
Infusion of CD4+ and CD8+ T lymphocytes transduced with a chimeric receptor 
containing the extracellular domain of human CD4 linked to the zeta chain of TCRs were 
followed by a decrease in the viral load and an increase in CD4+ T-cell counts. Upon 
recognition of TCR on the surface of HIV-infected T-cells, retrovirally-transduced T-
cells get activated and exhibit effector function such as cytokine production, antigen-
specific proliferation, and cytolysis of target cells (70). Other studies contradict these 
results and did not show any change in the HIV p24 or RNA plasma levels in patients 
that received cytotoxic T lymphocytes (CTL) transduced with CD4-ζ chimeric receptor, 
which indicates a lack of correlation between their in vitro and in vivo cytolytic 
 29 
capacity (71). 
Human cancer cells possess tumor associated antigens that can be recognized and 
bound by monoclonal antibodies. These antibodies can recognize the extracellular 
domain of these genes; an example is ERBB2 oncogene present in breast ovarian, gastric, 
and colon cancers. CR bearing scFv derived from the ERBB2 antibody linked to a hinge 
region and the zeta cytoplasmic domain were engineered, followed by transduction into 
CTL. The newly modified CTL were capable of efficient in vitro lysis of fibroblasts and 
epithelial cells transfected with human ERBB2 oncogene. Adoptive transfer of both 
target cells and CTL into nude mice slowed ERBB2 tumor growth for ten days (72).  
Based on the ability of monoclonal antibodies to recognize tumor associated 
antigens (TAA), cytotoxic T lymphocytes can be redirected using these antibodies in a 
clinical trial for metastatic ovarian cancer. One-third of the patients showed objective 
clinical responses, but the approach failed in most of them due to the limited accessibility 
of the solid tumors by antibodies, dissociation of antibodies from CTL, and the limited 
ability of re-directed T-cells to kill more than one cell (73). Another clinical trial using 
chimeric receptors was directed against renal cell cancer, an immunogenic tumor, with a 
specific monoclonal antibody, G250, that recognizes a carboxy-anhydrase expressed on 
the cell membrane in both primary tumors and metastases. A CR was engineered, bearing 
the scFv domains of G250 linked to the ζ-chain from Fc receptor of IgE and was 
administered to G250 positive patients  whose metastatic lesions were not amenable for 
resection in a phase I clinical trial protocol. Although infusions of T-cells retrovirally 
transduced with CR were clinically well tolerated, the patients developed liver toxicity 
and hyperbilirubinemia, but these laboratory abnormalities were reversible. This 
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phenomenon occurred due to the interaction of G250 antibody on the surface of gene-
modified T-cells with G250L target antigen also expressed on the cells lining the bile 
ducts. The CR-transduced T-cells were detected in the peripheral blood and showed 
increased specific cytolysis against G250L target cells and increased secretion of IFN-γ 
upon chimeric receptor stimulation (74). Another report has shown that a chimeric 
receptor designed to specifically recognize and target EBV was detected even 18 months 
after injection of EBV-specific CTL into patients (75). The long-term persistence and 
effects of therapeutic T-cells brings further hope for therapy with CRs.  
 Another caveat of immunotherapy with chimeric receptors is their functional 
limitations. There’s certainly an advantage of CRs designed to carry the variable region 
of an antibody as recognition domain and the zeta cytoplasmic moiety for signal 
transduction in the fact that they can activate T-cells to trigger antigens regardless of their 
MHC restriction. Still, there are differences between the interaction of CR-bearing T-
cells with their targets and a “classic” TCR interaction with a peptide held on a MHC 
molecule. These differences can lead to important functional issues. For the most part, 
upon recognition of a MHC-peptide complex, the CD4 or CD8 coreceptors are also 
recruited and interact with the nonpolymorphic regions of MHC class I or II, thus 
bringing lck (a tyrosine kinase from the Src family located in their cytoplasmic domain) 
in close association with ITAMs on the CD3 or ζ chains, leading to augmented activation 
of transcription factors and ultimately a more potent T-cell response. We can therefore 
assume that incorporation of CD4 or CD8 coreceptors might enhance the strength of CRs. 
Therefore, new CRs have been designed comprising multiple tandem linked signaling 
domains. These include zeta, CD4, CD28 with or without lck in different combinations 
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(zeta only, CD4-zeta, CD28-zeta). The presence of lck promotes signaling by CRs 
because it enhances receptor phosphorylation. CD4 cytoplasmic tail does not possess 
intrinsic kinase activity, but in the form of CR-CD4-zeta, it was shown to be able to 
enhance the phosphorylation of CR by recruitment of p56lck to the CR similar to the way 
lck on CD4 coreceptor is recruited by TCR. Overall, the novelty of this particular model 
of CRs is the improved signaling ability upon recognition of antigen when either CD4 or 
CD28 signaling regions are incorporated. T-cells transduced with these type of CRs show 
better proliferation and cytokine production than the ones having ζ only as signaling 
domain. Among all the combinations tried, the chimeric receptor with a CD28-ζ-lck 
intracellular signaling domain revealed to be the most efficient regarding IL-2 production 
and sensitivity to stimulation. However, its low surface expression level limited the 
practicality of using this receptor (76). 
An issue to be considered in the evaluation of therapeutic T-cells bearing CRs is 
the difference between their excellent in vitro effects and the poor in vivo survival and 
expansion of CR-expressing T-cells. For in vivo survival of transduced T-cells, proper 
stimulation and expansion is vital since prolonged culture of these cells might diminish 
their functional effects. Thus, the essence is fulfillment of the right conditions for T-cell 
stimulation since insufficient amounts of cytokines lead to passive cell death, whereas 
inappropriate stimulation leads to AICD. Another problem might be the need for CD4+ T-
cells presence. CD8+ T-cells can exercise their role in antigen clearance in the absence of 
any help in short-term acute infections. Chronic infections last longer and take more time 
to clear and CD4+ lymphocytes are required to sustain virus-specific CD8+ CTL (77). For 
example, CD8+ lysis ability seen in the late stages of acquired immunodeficiency 
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syndrome (AIDS) is lost in correspondence to a dramatic drop in the number of CD4+ T-
cells.  
In conclusion, adoptive immunotherapy with receptor-modified T-cells bearing 
chimeric receptors on their surface comprises a potential novel and specific therapy for 
malignancies and infectious diseases.  
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Chapter 3. Significance of a dileucine motif in CD28-zeta (ζ)-containing chimeric 
receptors 
 
3.1 Introduction 
Lysosomes are the ultimate destination of macromolecules transported from the 
extracellular space or cell membrane by endocytosis. These organelles can be accessed 
via internalization of carrier proteins into endosomes and then transportation to the 
lysosomes or via the biosynthetic pathway that involves an intermediate organelle, the 
trans-Golgi network, followed by intracellular delivery to endosomes and then 
lysosomes. Sorting of transmembrane proteins to endosomes and lysosomes is mediated 
by signals present in the cytosolic domain of the proteins. These signals include short 
amino acid sequences that can be tyrosine-based or dileucine motifs. There are two 
consensus dileucine motifs, [DE]XXXL[LI] or DXXLL. Dileucine (LL) motifs only have 
four to seven amino acid residues, but only two or three of them are critical for their 
function. These are recognized by proteins that play an important role in the endosomal-
lysosomal system. Clathrin coats forming around plasma membrane contain 
heterotetrameric adaptor protein (AP) complex AP-2 and other accessory factors. 
Endosomal clathrin coats and the trans-Golgi network contain AP-1 and ADP-
ribosylation factor-binding proteins (GGA1, 2, and 3) and monomeric adaptors. 
[DE]XXXL[LI]  sorting signals are recognized by the µ and β subunits of AP-1, AP-2, 
AP-3, and AP-4, leading to internalization, lysosomal, and basolateral targeting. DXXLL 
are recognized by the VHS domain GGAs, leading to sorting from the trans-Golgi to 
endosomes (78). 
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The dileucine motifs have been identified in multiple proteins in a quest to 
characterize protein motifs responsible for lysosomal targeting. For example, to eliminate 
multiple targeting signals, Letourneur engineered chimeras containing the extracellular 
and transmembrane domain of IL-2 receptor antigen Tac (the alpha chain of the IL-2 
receptor) linked to the cytoplasmic domain of each CD3 chain. Using these chimeras, a 
new dileucine-based targeting sequence in the cytoplasmic domain of CD3 γ and δ was 
revealed, responsible for both rapid internalization and delivery to lysosomes (79). This 
sequence shown to be important in lysosomal targeting contains six amino acids, 
DKQTLL; site-directed mutagenesis of either of the leucines L130 or 131 established 
their ranking. The first leucine is invariant since replacement with any other amino acid 
lead to decreased signal, whereas the second leucine could be replaced by isoleucine 
without affecting the function.  
 
3.1.1 [DE]XXXL[LI] signals 
The [DE]XXXL[LI]  signals are important in the sorting of many transmembrane 
proteins, such as: CD3-γ (human Tm-8-SDKQTLLPN-26), tyrosinase (human Tm-8-
EEKQPLLME-12), CD4 (human tm-12-SQIKRLLSE-17), etc. In CD3-γ chain, 
SDKQTLL sequence plays a part in serine phosphorylation-dependent downregulation of 
the TCR from the surface that involves rapid internalization and lysosomal degradation. 
CD4 has a very similar LL-containing sequence.  
As previously mentioned, [DE]XXXL[LI] signals are recognized by the µ and β 
subunits of various AP complexes. Each [DE]XXXL[LI] signal has a preference for a 
specific AP complex but not others. Although they bind to the µ2 subunit of AP (similar 
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to tyrosine-based motifs), these determinants do not compete with each other.  
 
3.1.2 DXXLL signals 
DXXLL signals constitute a particular type of sorting determinants present in 
proteins or transmembrane receptors that cycle between the trans-Golgi and endosomes, 
such as cation-independent (CI-MPRs) or cation-dependent mannose-6-phosphate 
receptors (CD-MPRs). These signals mediate incorporation into clathrin-coated vesicles 
that move from the Golgi apparatus to the endosomal system. Similar to [DE]XXXL[LI] 
signal, this has a very strict requirement for the LL and also D residues, because 
mutations of any of these amino acids inactivate signaling and increase the protein 
expression at the cell surface (80). This signal does not bind to AP complexes but instead 
is recognized by the amino terminal VHS domain of GGAs, which are ADP-ribosylation 
factor-dependent clathrin adaptors within the trans Golgi and endosomes (81). This 
recognition is very specific since the VHS domain cannot bind the other dileucine motif, 
[DE]XXXL[LI], or the tyrosine motif YXXø. Regulation of the recognition of DXXLL 
signals also involves serine residues in a consensus sequence placed two or three amino 
acids upstream of DXXLL signals that are phosphorylated by casein kinase II (CK II). 
Upon phosphorylation of serine, the negatively charged oxygens in the phosphate group 
interact with the positively charged residues within the VHS domains of GGAs. Upon 
this interaction, MPRs are incorporated into clathrin-coated vesicles emerging from the 
trans-Golgi network. These vesicles will then deliver the receptors to endosomes and 
eventually, to lysosomes (82). Another interaction involves GGA 1 and 3 that also bear 
DXXLL motifs able to bind their own VHS domain (83), followed by auto-inhibition. 
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Therefore, GAs should be dephosphorylated in order to displace from their own VHS 
domain, making it available for interaction with domains in the cytosolic part of other 
proteins.  
 
3.2 Identification of a murine CD28 dileucine motif that suppresses single-chain 
chimeric T-cell receptor expression and function (1) 
 
3.2.1 Introduction 
 RMTC are T-cells modified to express surrogate chimeric receptors that can 
target antigens not normally recognized by the immune system. These chimeric receptors 
that redirect therapeutic RMTC against their targets substitute for the classic T cell 
receptor. They recognize target antigen through an extracellular antigen-recognition 
domain, such as a single-chain Fv fragment, and signal through a TCR-derived signal 
transduction domain, such as the TCR ζ chain (84).  RMTC have shown therapeutic 
properties in cancer of infectious diseases systems, selectively targeting malignant or 
infected cells in model systems. No significant toxicity has been observed in phase I 
clinical trials (85). 
A possible problem in redirecting therapeutic cells with chimeric receptors is the 
limited signal the receptors are able to transduce. The physiologic coreceptor and 
costimulatory signals that are normally delivered to T-cells when they interact with an 
APC are not necessarily available in the case of RMTC engaging with the ligand on a 
target cell. These signals are important, for they promote T cell survival, proliferation, 
and effector function. To avoid this drawback, we have developed single-chain chimeric 
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receptors that incorporate moieties from both the TCR and costimulatory and/or 
coreceptor molecules. We decided to genetically link the signaling domain of the CD28 
costimulatory molecule to the cytoplasmic tail of the TCR ζ chain. Several studies have 
shown that RMTC that express chimeric receptors composed of a CD28-ζ signaling 
region showed improved functional responses compared to those that only bear the ζ 
signaling tail. 
In our study, we used RMTC to specifically target T lymphocytes. Some RMTC 
may be useful in transplantation or other settings. The specificity of the TCR is the 
defining feature of a pathologic T cell. In transplantation, these TCR are generally 
directed against allogeneic major histocompatibility complex (MHC) or syngeneic MHC 
linked to minor histocompatibility antigens. We designed surrogate CRs to specifically 
redirect RMTC against class I MHC-restricted T-cells. These CRs include the 
extracellular and transmembrane domains of the MHC class I Kb molecule linked to either 
a murine ζ or CD28-ζ signaling tail. The Kb extracellular region serves as bait for Kb-
restricted T-cells; the signaling domain promotes the RMTC’s effector functions. 
Biochemical analysis of CR-mediated signal transduction in Kb-CD28-ζ or Kb-ζ-
transduced T cell hybridoma showed that the presence of CD28 enhanced receptor 
phosphorylation and calcium flux. Furthermore, the CD28 domain allowed direct receptor 
association with the src kinase p56lck, critically involved in initiating and sustaining 
receptor-mediated signal transduction. Kb-CD28-ζ T cell hybridoma also showed 
increased IL-2 production and signaling sensitivity.  
Unlike these data with hybridoma, when we transduced primary murine T 
lymphocytes with the CD28-ζ or the ζ-CR, we did not observe significant differences in 
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chimeric receptor-mediated functional responses (82). We further observed a 2-fold to 4-
fold decrease in the surface expression level of the Kb-CD28-ζ CR in primary T-cells 
when compared with the Kb-ζ receptor. Therefore, addition of the CD28 costimulatory 
molecule in chimeric receptor leads to conflicting effects: it provides an enhanced signal 
into RMTC but at the same time diminishes the receptor surface expression and thus 
limits the extent and/or duration of this signal. 
In order to find a sensible explanation for the decreased expression of the Kb-
CD28-ζ CR, we analyzed the sequence of the murine CD28 cytoplasmic tail and we 
noticed a noncanonical dileucine internalization motif. Dileucine motifs have been well 
characterized in other proteins, but not CD28. To clarify the role of this motif in the 
CD28-ζ CR function, we inactivated it by mutating leucine to glycine, [L G]. We found 
that this mutation increased surface expression of the Kb-CD28-ζ receptor 2-fold to 5-fold 
compared with the wild type receptor. Moreover, Kb-CD28[L G]-ζ-modified T-cells 
showed increased sensitivity in cytokine production, proliferation, and cytolysis of target 
cells when compared with Kb-CD28-ζ RMTC. Therefore, this study identifies a 
previously undescribed dileucine motif within the murine CD28 tail and demonstrates its 
specific role in the restriction of CR function in RMTC. 
 
3.2.2 Materials and methods 
 
3.2.2.1 Construct 
cDNA clones or splenic cDNA were used to isolate cDNA fragments encoding 
the extracellular and transmembrane domain of the H-2Kb molecule and the cytoplasmic 
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tails of murine CD28 and ζ by PCR. Flanking restriction sites were added to the 
fragments by PCR and the dileucine mutation was introduced by PCR mutagenesis. The 
constructs were assembled and subcloned into the MSCV retroviral vector that contains 
an internal ribosome entry site (IRES) linked to the green fluorescence protein (GFP) (gift 
from E. Vanin, St Jude Children's Research Hospital). Prior to ligation of all genes into 
the final construct, all DNA sequences were confirmed by sequencing at the St Jude 
Hartwell Center for Biotechnology.  
 
3.2.2.2 Antibodies, cells, mice 
TG-B transgenic mice were used as a source of CD8+ T-cells for transducing the 
two constructs. These mice are transgenic for a rearranged SV40-T/H-2Kk-restricted TCR 
that were bred more than 20 generations with B10.BR mice. As a source of target cells 
we used OT-1 mice (Jackson Laboratories, Bar Harbor, ME), transgenic for a rearranged 
ovalbumin 257-264/H-2Kb-restricted TCR. Antibodies included clone B20.1 anti-mouse 
V 2 (Pharmingen, San Diego, CA), clone 2C11 anti-mouse CD3  (gift from M. 
Blackman, Trudeau Institute, Saranac, NY), clone AF6-88.5 anti-mouse H-2Kb 
(Pharmingen and gift from M. Blackman), goat anti-mouse IgG (Jackson Laboratories), 
and goat anti-rat IgG (Jackson Laboratories).  
 
3.2.2.3 Retroviral transduction and T cell culture  
10 µg of CR constructs and 10 µg of the retrovirus helper DNA PEQPAM (gift 
from J. Cleveland) were cotransfected into 293 T cells using calcium phosphate 
precipitation. After 16 hours, the cells were washed and cultured in Dulbecco modified 
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Eagle medium/10% fetal calf serum (DMEM/10% FCS) for 48 hours. Supernatant was 
collected twice daily and used to infect GP+E86 retroviral producer cells in the presence 
of 8 µg/mL polybrene, for five days. Transduced GP+E86 cells were sorted for GPF by 
fluorescence-activated cell sorting (FACS). To transduce T lymphocytes, we isolated 
lymph nodes, processed them in a single-cell suspension, and stimulated them in vitro 
with soluble anti-CD3- and CD28 antibodies in the presence of 2 ng/mL recombinant 
murine IL-2 (rmIL-2) (R&D Systems, Minneapolis, MN) for 48 hours. At that point, the 
medium was replaced with retroviral supernatant and 8 µg/mL polybrene, and the cells 
were spun at 1800 rpm for 90 minutes in a Jouan CR422 tabletop centrifuge (Winchester, 
VA). Transduced T-cells were sorted for expression of GFP and CD8 and expanded in 
EHAA medium (Biosource International, Camarillo, CA) in the presence of rmIL-2 for 
up to 5 days. The cells were restimulated every 10 days using 2 µg/mL Concanavalin A 
(ConA; Sigma, St Louis, MO), 2 x 106/mL irradiated syngeneic splenocytes (3000 rad), 
and 2 ng/mL rmIL-2. The assays were performed on day five or six after stimulation, in 
the absence of exogenously added IL-2.  
 
3.2.2.4 Proliferation  
96-well plates were coated with goat anti-mouse IgG followed by loading of 
purified AF6-88.5 antibody. 5 x 104 CR-transduced T-cells and 2.5 x 105 25 irradiated 
syngeneic B10.BR splenocytes were added. After 48 hours, the cells were pulsed with 1 
µCi 3[H]-thymidine for 16 hours and harvested onto filtermats. Liquid scintillation 
counting of incorporated thymidine was used to assess proliferation. All samples were 
analyzed in triplicate and plotted as means.  
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3.2.2.5 Cytotoxicity assay  
RMTC were incubated overnight in medium with different concentrations of 
ovalbumin (OVA) 257-264 peptide (St Jude Hartwell Center for Biotechnology) in PBS 
or control PBS, then washed 3 times and resuspended in medium. Effector RMTC were 
incubated with 105 OT-1 target T-cells in various ratios. The target cells were isolated 
from OT-1 TCR transgenic lymph node cells or splenocytes. After 5 to 6 hours of 
coincubation, 5000 to 10 000 6-µm fluorescent TruCount beads (Becton Dickinson, 
Franklin Lakes, NJ) were added. Samples were stained for V 2, washed once, and 
analyzed by flow cytometry. The target cells stained positive for V 2 and GFP negative, 
and were readily distinguished from the GFP+ effector cells. The TruCount beads serve as 
a tool for normalization of cellular events and provide a quantitative assessment of the 
absolute number of target cells. Percent specific cytotoxicity was determined as 100 x (1 - 
viable target cell count after incubation with peptide-pulsed effectors/viable target cell 
count after incubation with unpulsed effectors). Parallel cultures of target cells in the 
absence of effector cells were performed simultaneously in all experiments as negative 
controls. Essentially identical results were obtained when cytotoxicity was alternatively 
calculated as 100 x (1 - viable target cell count after incubation with peptide-pulsed 
effectors/viable target cell count after incubation without effectors). All samples were 
analyzed in quintuplicate. 
 
3.2.2.6 Cytokine analysis  
IFN-γ was analyzed using a Bioplex assay (Bio-Rad, Hercules, CA). 3000 
analytical beads per well were added to a prewet 96-well filter plate. The samples were 
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then added to the beads and incubated for 1 hour at room temperature (RT), followed by 
aspiration of supernatant, beads washing, and incubation for 1 hour with biotinylated anti-
IFN-γ detection antibody. Detection was performed by staining with streptavidin-
phycoerythrin (PE) and fluorescence analysis with a Bioplex plate reader (Bio-Rad).  
 
3.2.3 Results 
 
3.2.3.1 Design and expression of chimeric receptors  
H-2Kb extracellular and transmembrane domains were linked to the cytoplasmic 
domains of CD28 and ζ in order to engineer the wild-type Kb-CD28-ζ and dileucine-
mutated Kb-CD28[L G]-ζ receptors (Figure 3-1). Both constructs were subcloned into 
the MSCV retroviral vector, which includes an IRES and GFP gene. Upon transduction of 
primary CD8+ T lymphocytes with retroviral supernatant, we observed efficiencies 
ranging from 15% to 50%.  
To determine the role of the dileucine motif in CR expression, CD8+GFP+ T-cells 
transduced with either the Kb-CD28-ζ or Kb-CD28[L G]-ζ receptor were sorted and 
stained with a Kb-specific antibody. We noticed a 2-fold to 5-fold increase in the surface 
expression level in the cells bearing the mutated receptor compared to the wild-type one, 
regardless the amount of GFP cotranscribed in the cells (Figure 3-2). These results 
demonstrate that the dileucine motif in the CD28 molecule significantly restricts the level 
of surface chimeric receptor, while its disruption enhances surface expression, but this 
finding does not necessarily ensure a more robust functional response. 
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Figure 3-1. Chimeric receptor structure and sequence of the dileucine motif. 
Chimeric constructs were created by linking components in a cassette fashion. 
Extracellular and transmembrane domains are derived from the MHC class I H-2Kb 
molecule. The murine CD28 and TCR-ζ cytoplasmic tails were attached as described.10 
PCR mutagenesis was used to introduce the leucine to glycine change in the CD28 tail. 
This corresponds to an L184G and L185G conversion in the CD28 sequence (GenBank 
accession NP_031668).  
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Figure 3-2. Increased surface expression of dileucine-mutated chimeric receptor. 
Chimeric receptor (anti-Kb) expression is plotted as a function of cotranscribed GFP 
level. Transduced cell populations were analyzed for GFP (FL1) expression level and 
gated into regions comprising approximately 0.2 to 0.3 log fluorescence using Cellquest 
software (BD Biosciences, San Jose, CA). For cells within each of these gated regions, 
FL1 MFI (GFP) and FL2 MFI (anti-Kb staining or control unstained) was calculated and 
plotted. 
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3.2.3.2 Functional response of RMTC  
Previous data has shown that the T cell response to stimulation depends on the 
intensity and duration of the stimulus. This implies that the increased expression of [L
G] chimeric receptors should theoretically result in improved signaling compared with the 
wild type receptors. However, since the role of the dileucine motif in CD28 signaling has 
not been established yet, it is also possible that this disruption would hinder signal 
transduction. To determine whether this mutation proves beneficial on the functional 
response or not, we first measured T cell proliferation after stimulation through both 
receptors using a non-specific mitogen. Kb-CD28-ζ, Kb-CD28[L G]-ζ, and MSCV 
retroviral control cells responded equivalently to Concanavalin A. This result 
demonstrates that the expression of CR does not affect the proliferative ability of 
therapeutic, CR-transduced T-cells in response to non-specific stimuli (Figure 3-3). In 
contrast, differences were observed after stimulation through the CR. T-cells transduced 
with the [L G]-mutated CR proliferated better than wild type CR-transduced T-cells in 
response to CR-specific stimulation. Therefore, we can conclude that the dileucine motif 
in CD28 functionally restricts chimeric receptor activity, and the L G mutation alleviates 
this restriction. 
To determine whether the enhanced function of mutated CR-transduced RMTC 
also affected the amount of cytokines produced by T-cells upon stimulation, we analyzed 
IFN-γ secretion. A more than 3.5-fold IFN-γ production was noted upon stimulation of 
Kb-CD28[L G]-ζ RMTC with CR-specific antibody (Figure 3-4). Therefore, disabling 
the dileucine motif also improves RMTC cytokine response.  
 It was already proven that Kb-CD28-ζ RMTC can kill Kb-restricted target cells 
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Figure 3-3. Proliferative response of Kb-CD28- ζ and Kb-CD28[L G]-  RMTC. 
GFP-sorted CD8+ RMTC were stimulated 7 days after transduction with irradiated 
splenocyte feeders on plates coated with AF6-88.5 anti-H-2Kb or in the presence of the 
nonspecific mitogen conA. After 2 days the cultures were pulsed with 3H-thymidine and 
harvested 16 hours later. Data points are means of triplicate samples. Error bars show ± 1 
SD. One of 3 essentially identical experiments is shown. 
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Figure 3-4. IFN-  production by Kb-CD28-  and Kb-CD28[L G]-  RMTC. GFP-
sorted CD8+ RMTC were stimulated 7 days after transduction in the presence of 
splenocyte feeders on plates coated with 5 µg/mL AF6-88.5 anti-Kb, with conA, or 
cultured in the absence of stimulation. Stimulation-induced IFN-  production was 
measured by Bioplex assay using anti-IFN- -coated beads. Data points are means of 
triplicate samples. Error bars show ± 1 SD; *, less than 1 ng/mL. 
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(58). We tested if the new mutated CR is more efficient in this aspect. We used OT-1 
cells from the lymph nodes or spleen of mice transgenic for a TCR specific for Kb/Ova 
257-264 as target cells. Ova peptide-pulsed Kb-CD28[L G]-ζ RMTC are able to 
specifically kill target OT-1 T-cells more efficiently than the Kb-CD28-ζ RMTC (Figure 
3-5). This is a confirmation that the dileucine to glycine mutation enhances the effector 
function of RMTC, namely the ability to proliferate, secrete cytokines, and lyse Ova-
specific target cells.  
The data above show that mutations in the dileucine motif of CD28 enhance the 
effector function of RMTC in vitro. We next wanted to find out if therapeutic cells were 
also effective in vivo. To do this, we coinjected Ova peptide-pulsed RMTC transduced 
with the wild type or mutated CR along with OT-1 transgenic cells labeled with 
carboxyfluorescein succinnimidyl ester (CFSE) into severe combined immunodeficiency 
(SCID) mice. Both Kb-CD28[L G]-ζ and Kb-CD28-ζ peptide-pulsed RMTC efficiently 
eliminated OT-1 T-cells. This means that the mutated CR-transduced therapeutic cells are 
functional in vivo. These cells also show a slight – though not statistically significant – 
increase in the cytolytic activity compared to the unmutated CR-transduced RMTC, 
which might be an indication for their preferential use in the future (Figure 3-6). 
 
3.2.4 Conclusions 
 T-cells redirected against pathologic lymphocytes are potential tools in cellular 
immunotherapy. Therapeutic cells can migrate to different sites in the body, are long-
lasting, and exhibit different effector functions. Chimeric receptors composed of antigen-
recognition and signaling domains from the TCR, such as the cytoplasmic ζ tail, were  
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Figure 3-5. Cytolysis of antigen-specific T-cells by Kb-CD28-  and Kb-CD28[L G]-
RMTC. (A) RMTC were pulsed with 50 µg/mL ovalbumin 257-264 peptide or saline 
diluent, washed, and cultured for 6 hours with OT-1 TCR transgenic T lymphocytes at 
the designated effector-target ratio. Target cell survival was determined using 
quantitative flow cytometry. Specific cytolysis was calculated from the number of 
residual viable target cells in wells containing target cells pulsed with peptide compared 
with that in otherwise identical control wells including unpulsed effectors. (B) Similar to 
panel A, except experimental RMTC were pulsed with the designated concentration of 
ovalbumin peptide. All samples were cultured at an effector-target ratio of 1. Data points 
are means of quintuplicate samples. Error bars show ± 1 SD. Plots are representative of 3 
independent experiments. 
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Figure 3-6. In vivo killing of antigen-specific T lymphocytes using Kb-CD28-  and 
Kb-CD28[L G]-  RMTC. A total of 107 CFSE-labeled OT-1 lymph node cells were 
adoptively transferred intravenously into SCID mice; 107 Kb-CD28-ζ or Kb-CD28[L
G]-ζ peptide-pulsed or unpulsed RMTC were then adoptively transferred intravenously at 
an anatomically separate location. Twenty-four hours after transfer, spleen and mixed 
lymph nodes (mesenteric, cervical, axillary, inguinal) were isolated and single-cell 
suspensions prepared, stained with V 2-specific antibody, and analyzed by flow 
cytometry. (C) Normalized numbers of target cells in the spleens of treated animals. The 
ratio of residual transferred (CFSE-positive) RMTC targets (Vα2-positive) to nontargets 
(Vα2-negative) was calculated to control for the efficiency of adoptive transfer in mice 
treated with peptide-pulsed or control unpulsed effectors. (D) Analysis of LN cells. Error 
bars show ± 1 SD. Results are representative of 3 independent experiments.  
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proven effective in redirecting T-cells against target cells. Since their effector abilities 
depend upon the efficiency of signal transduction and the presence of costimulatory 
molecules, new generation of CRs include both the CD28 molecule and the ζ tail. 
Although we and others have observed enhanced function of the CR bearing the 
extracellular and transmembrane part of the Kb molecule linked to CD28-ζ in T cell 
hybridoma, there was no noticeable difference between the functional effectiveness of 
this construct compared to the one lacking CD28 when transduced into primary murine 
T-cells. Also, the surface expression of this CR was diminished. We hypothesized that 
the poor expression resulted in the lack of improvement of their effector abilities. We 
here identify a novel dileucine motif in the murine CD28 molecule that hampers CR 
expression and function.  
 Up to now, two classes of dileucine motifs have been described, containing 
[DE]XXXL[LI] or DXXLL. They play critical roles in the sorting of transmembrane 
proteins. DXXLL signals are distinct dileucine-based sorting signals that cycle between 
the trans-Golgi network and endosomes and mediate incorporation into clathrin-coated 
vesicles that bud from the trans-Golgi network for transport to the endosomes. They bind 
to the GGA family of ARF-dependent clathrin adaptors localized in the trans-Golgi 
network. Mutations of either D or LL upstream inactivate the signals and result in 
increased surface expression of the proteins. [DE]XXXL[LI] motifs bind to AP-1, 2, or 3 
and are less intolerant to mutations of the second isoleucine that can be mutated without 
impairing activity (74). The SRRNRLL that we discovered in the CD28 molecule is not 
identical to either [DE]XXXL[LI] or DXXLL motifs; rather, it is more similar to a 
[DE]XXXL[LI] motif that can also be found in other molecules, such as human CD4 
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(SQIKRLLSE), mouse GLUT4 (RRTPSLLEQ) or human VAMP4 (SERRNLLED). This 
motif has a positively charged arginine residue upstream the dileucine motif instead of 
the canonical negatively charged amino acid residues.  
Our experimental results disentangle the functional properties of the dileucine 
motif in CD28 molecule. Although disruption of this motif leads to enhanced surface 
expression and effector function, internalization might not be directly related to this fact. 
CD3γ molecule also has a SDKQTLL sequence responsible for internalization of the 
TCR but only after phosphorylation of serine (80). It is therefore, possible that 
internalization requires a conformational shift that makes the motif accessible to sorting-
associated proteins. In our CR, the CD28 tail was taken out of its normal 
environment/structure, possibly making the dileucine motif more exposed to the protein-
sorting apparatus, and leading to its constitutive activation. 
The dileucine motif in CD28 limits the CR expression and signaling when 
transduced into primary murine T-cells. Mutation of leucine residues to glycine improves 
surface expression and upregulates proliferation, cytokine secretion, and cytolysis of 
target cells. 
In addition to the in vitro evidence, we also provide evidence that effector T-cells 
bearing CR with mutated dileucine motifs are active in vivo, leading to selective killing 
of specific target cells. This constitutes a possible future therapeutic approach in 
transplant tolerance and autoimmunity.  
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Chapter 4. Development and function of humanized chimeric receptors 
 
4.1 Introduction to the development of humanized chimeric receptors  
 Surrogate chimeric receptors designed to bear an antigenic peptide linked to parts 
of MHC class I or II molecule and signaling parts of the TCR may be used as therapeutic 
tools (57). These CRs can be transduced into T lymphocytes giving rise to receptor-
modified T-cells designed to specifically target only pathogenic, peptide-specific T-cells. 
In initial studies our laboratory used a T-lineage specific promoter to express in 
transgenic mice a chimeric receptor that included the immunodominant epitope of myelin 
basic protein (MBP) in SJL mice linked to its restricting I-As MHC and the signaling 
domain of TCR-ζ.  MBP-specific T-lymphocytes stimulated these transgenic RMTC, 
inducing effector functions, such as cytokine secretion, proliferation, and/or cytolysis of 
target cells.  CD8+, T helper 2, or CD4+CD25+ transgenic RMTC showed therapeutic 
activity in EAE, even after the dissemination of T cell responses through epitope spread 
(55).  These data supported the application of RMTC immunotherapy in autoimmune 
diseases. 
I have examined whether RMTC carrying humanized CRs can be similarly 
redirected against autoantigen-specific T lymphocytes. These humanized CRs were 
engineered by genetically linking autoantigenic peptide, MHC, and TCR-ζ or other 
signaling domains. The MHC-Ag serves as bait that specifically recognizes the TCR of 
autoantigen-specific T lymphocytes. Cognate TCR recognition of the extracellular MHC-
Ag crosslinks the chimeric receptor, activating the RMTC through the receptor’s 
signaling domains.  
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Linkage analyses have associated HLA-DR2 (DRA*01/DRB1*1501) in patients 
of European descent with susceptibility to MS. Additionally, reactivity to a specific 
epitope, MBP84-102, restricted to this HLA has been well characterized in patients with 
MS (86). In this study we took advantage of this established association to design two 
chimeric receptors specific for DR2-restricted, MBP84-102-specific T-cells.  Each 
heterodimeric receptor includes an extracellular and transmembrane domain comprised of 
HLA DRA*0101/DRB1*1501 with genetically linked MBP84-102 peptide.  One receptor 
pair incorporates the cytoplasmic ITAM-rich domain of TCR-ζ on both the α  and β 
chains (MBP-DR2-ζ).  The second receptor pair lacks these signaling chains (MBP-
DR2), allowing us to define the role of receptor signaling in therapeutic cell function, 
which we were unable to do with the transgenic cells in our previous mouse model. The 
receptors were placed in an MSCV-based retroviral vector to allow us to determine 
whether adoptively transferred T-lymphocytes retrovirally transduced with the tri-
cistronic (α, β receptor, GFP) chimeric constructs are functional, able to re-direct effector 
activity, and capable of modulating autoimmune disease in a humanized model system. 
In this chapter, I describe our efforts to create humanized chimeric receptors and 
validate them through in vitro studies of the therapeutic cells’ effector abilities.  The 
receptors were transduced into two types of effector cells, immortalized TCR-CD4-CD8- 
4G4 T-cell hybridoma and primary CD8+ T lymphocytes.  The activity of the receptors 
against cognate MBP84-102/DR2-specific T-cells was tested using either a hMBP84-
102-specific Ob1A12 T-cell hybridoma (or Ob hybridoma), a T-cell clone derived from a 
patient with relapsing-remitting multiple sclerosis, or T-cells from mice made transgenic 
with rearranged TCR derived from the Ob hybridoma, Ob Tg mice (87). These Ob Tg 
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mice were bred with another strain that constitutively expresses human DR2 gene using 
the human DR2 promoter (Fug 5 mice) (88). As a negative control for our in vitro studies 
we used 6F11 T cell cell hybridoma specific for MBP89-101 epitope (same as hMBP 84-
102) restricted by I-As. 
 
4.2 Materials and methods 
 
4.2.1 Design of humanized MBP-DR2-ζ construct 
 The MBP-DR2-ζ construct contains two polypeptides. The first one includes the 
extracellular and transmembrane domains of the human MHC class II beta chain 
DRB1*1501 linked to the human MBP peptide epitope 84-102 and the ζ cytoplasmic 
domain of the TCR. This was then linked to the human MHC class II alpha chain 
DRA*0101 paired with the ζ cytoplasmic tail of TCR. The alpha and beta chains were 
connected by a small amino acid sequence extracted from the Thosea asigna virus (TaV). 
We cloned the two genes in a single open reading frame by eliminating the stop codon at 
the end of the first ζ tail. The 2A sequence allows for polycistronic message formation.  
As the mRNA is translated, the ribosome pauses at the 2A sequence and cleaves the N-
terminal peptide from the nascent protein product.  The ribosome does not release the 
mRNA however, and continues to synthesize the C-terminal polypeptide.   Following 
cleavage, the 2A peptide remains attached to the C-terminus of the first gene. The 
advantage of this bicistronic system using 2A sequences is the same amount of two 
distinct proteins, α and β chains of the chimeric construct, is produced (89). Internal 
ribosomal entry sites (IRES) can also be added to mRNA to permit for polycistronic 
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message production, however, variable translational efficiencies are observed from the 5’ 
mRNA cap and the IRES, leading to non-stoichiometric protein production. This 
synthetic heterodimeric gene was subcloned into the murine stem cells virus (MSCV) 
retroviral expression vector that contains an IRES-linked green fluorescent protein 
(GFP) for an easy identification of the gene by fluorescence activated cell sorting (FACS) 
analysis.  
 
4.2.1.1 Generation of leader sequence  
 We started by extracting total RNA from MGAR cell lines using RNeasy 
procedure (Qiagen, Valencia, CA). MGAR cells are Epstein-Barr virus (EBV)-
transformed B cells that express DRA*0101/DRB1*1501. We used the following 
protocol:  
 10x106 MGAR cells were counted and spun for 5 minutes in a centrifuge tube. 
The supernatant was discarded and 600 µl lysis buffer RTL (Quiagen) containing 10 
µl/ml 2-mercaptoethanol was added to the pellet which was then resuspended by 
vortexing. The disrupted cells were then homogenized by pipetting the lysate directly 
onto a QIAshredder column followed by a 2 minute-centrifugation in a microcentrifuge at 
maximum speed and collection of the homogenized lysate. One volume (600 µl) of 70% 
ethanol was added to the homogenized lysate, mixed, applied to an RNeasy minispin 
column carried by a 2-ml collection tube, and centrifuged for 15 seconds at 8000 x g. 
This step was repeated until the whole volume was used and the flow-through was 
discarded every time. 700 µl buffer RW1 (Quiagen)  was added to the column and 
centrifuged again like above, followed by transfer of the column onto a new collection 
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tube and addition of 500 µl buffer RPE (Quiagen) and another step of centrifugation. We 
repeated this step twice. The column was ultimately transferred again to a new collection 
tube and 30 µl of RNase-free water was added to the RNeasy membrane to elute RNA. 
We obtained 194 µg/ml total RNA that was stored at -80˚C. 
 After RNA extraction, we performed reverse transcription polymerase chain 
reaction (RT-PCR) using the standard Omniscript protocol (Qiagen) for first-strand 
complementary DNA (cDNA) synthesis as follows: 
  Tube 1: 10 µl mix containing 2 µl RNA (thawed on ice) and 8 µl RNase-free 
water was heated at 65˚C for 5 minutes. 
 Tube 2: 10 µl mix of oligo d(T) primer (12 nucleotides) at a final concentration of 
1 µM, 10x RT buffer, dNTP mix, 1 µl RNasine, RT enzyme, and water. 
 Tube 2 mix was added to tube 1 mix and kept for an hour at 37˚C. The single-
stranded cDNA obtained can be kept at -20˚C or PCR for the genes of interest using 
specific primers can ensue.  
 Exon 1 from HLA-DRB1 encodes the leader peptide (GenBank Accession # NM 
002124; accessed on April 3, 2003). A Kozak sequence for initiation of translation in 
vertebrates (90) was introduced by PCR and the whole piece was flanked by EcoRI and 
NheI restriction sites. The set of primers used for this reaction was: 
 Primer 1: 5’-GATCAGAATTCGCCACCATGGTGTGTCTGAAGCTCCCTGG 
 
 
Primer 2: 3’-TTCATCGCTAGCCAAAGCCAGTGGGGAGCTCAGCAC  
 
 We set up a PCR using MGAR cDNA and this set of primers as follows: 100 µl 
NheI 
EcoRI Kozak 
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reaction mix containing 2 µl cDNA, 10 µl buffer and magnesium chloride (MgCl2), 2 µl 
dNTPs, 2 µl primer 1, 2 µl primer 2 (at a concentration of 25 pmol/µl), 0.5 µl high fidelity 
Taq polymerase and 81.5 µl water was submitted to 35 cycles of amplification using the 
following set-up:  
 First cycle of amplification: denaturation 5 minutes at 94˚C, annealing 2 minutes 
at 55˚C, extension 3 minutes at 72˚C. 34 subsequent cycles followed using a gradient for 
the annealing step, starting at 65˚C and subtracting 0.2˚C each cycle until it reached 
55˚C. We checked the size of the leader sequence on a 1% agarose gel and we obtained 
the expected size of 101 base pairs (bp). The PCR product was submitted for sequencing 
in a tube of 12 µl total mix containing 1 µl of DNA, 1 µl of each primer, forward (primer 
1) and reverse (primer 2) at 3.2 pmol, and water at the Hartwell Center, St. Jude 
Children's Research Hospital. 
 Once the product was proven correct, we used the two enzymes, EcoRI and NheI, 
to digest the leader sequence, gel purify it, and subclone it into pBluescript (pBS) II KS 
(+) vector (Stratagene, La Jolla, CA) digested with the same enzymes. 
 
4.2.1.2 Generation of MBP peptide sequence 
 NCBI nucleotide search found the sequence for Homo sapiens MBP (GenBank 
Accession # NM 002385; accessed on April 30, 2003).The MBP epitope 84-102 
(DENPVVHFFKNIVTPRTPP) was synthesized as oligonucleotides by the Hartwell 
Center at St. Jude Children's Research Hospital, Memphis, TN. The oligonucleotides 
used have the following sequence: 
 Forward primer: 5’-CTAGCGATGAAAACCCCGTAGTCCACTTCTTCAAGA 
NheI 
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Reverse primer: 3’-GATCCGCCTGACCCTCCGCCACCGGACCCGCCACCTCCG 
 
GGTGGTGTGCGAGGCGTCACAATGTTCTTGAAGAAGTGGACTACGGGTTTTC
ATCG 
 These two oligos were mixed in a 1:1 ratio, annealed at 94˚C, cooled down at 
room temperature, and ligated it together with EcoRI/NheI-digested leader sequence into 
pBS II KS vector using T4 DNA ligase (New England BioLabs, Ipswich, MA). This 
time, the vector was digested with EcoRI (that the leader sequence has a site for) and 
BamHI (present at the end of the peptide sequence or beginning of the beta chain). We 
ended up with the following piece of 185 bp that we sequenced and confirmed to be 
correct: 
 
 
 
 
 
4.2.1.3 Generation of HLA-DRB1*1501 
  NCBI nucleotide search found the sequence for Homo sapiens HLA-DRB1 
(GenBank Accession NM_002124 on May 5, 2003) mRNA with exons 2 and 3 coding 
for the extracellular domains. We amplified the cDNA obtained as previously described 
(4.2.1.1) with the following set of primers, adding two restriction sites, BamHI and AatII: 
 Forward primer: 5’-TCAGGCGGATCCGGGGACACCCGACCACGTTTCTTG 
 
BamHI 
BamHI 
leader hMBP84-102EcoRI BamHI
NheI
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 Reverse primer: 3’-TCTTGACGTCTGATTCCTGAAGTAGATGAACAGCCC 
  
 PCR amplification yielded a 682 bp product. We subcloned this gene into pBS II 
vector digested with BamHI/AatII, sequenced this, and confirmed the correct sequence. 
 
4.2.1.4 Generation of the ζ chain 
 NCBI nucleotide search found the sequence for Homo sapiens CD3ζ (GenBank 
Accession NM_000734 on May 1, 2003)) mRNA. cDNA was provided by courtesy of 
Dr. Dario Campana, St. Jude Children's Research Hospital, Memphis, TN and amplified 
by PCR to obtain the cytoplasmic tail flanked by  AatII and ApaI restriction sites using 
the following set of primers: 
 Forward primer: 5’-AATCAGACGTCAAGAGTGAAGTTCAGCAGGAGCGCA 
  
 Reverse primer: 3’-GCCATGGGCCCGGGATTTTCCTCCACGTCCCCGCATGTT 
 
AGAAGACTTCCCCTGCCCTCGGCTCTGCGAGGGGGCAGGGCCTGCATGTGAA 
G 
 The reverse primer also included the reversed 2A sequence (discussed below), 
which was synthesized as part of the oligonucleotide. Similar to the other genes, the zeta-
2A gene was also sequenced, confirmed correct, and subcloned into pBS II vector. The 
product was 396 bp. 
 
 
AatII 
Aat II 
Apa I 
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4.2.1.5 The 2A sequence  
Thosea asigna virus (TaV) is a member of the Tetraviridae family comprised of 
single-stranded RNA picornavirus whose polyproteins undergo co-translational cleavage 
to produce several proteins (P1, P2, P3). The 2A sequence is a proteinase that cleaves at 
its own amino terminus generating two protein products, P1 and P2. The 2A sequence 
was previously used in retroviral vectors as an alternative system to IRES to generate a 
polycistronic message (91). In the MBP-DR2-ζ and MBP-DR2 constructs the 2A 
sequence is flanked by α and β chimeric receptor chains forming a unique open reading 
frame. The cleavage of the polyprotein product occurs at the C-terminus end of the 2A 
sequence, leaving it fused to the upstream β chain protein which is otherwise released 
intact. The amino acid sequence of the 2A was: 
 5’-RAEGRGSLLTCGDVEENPGP-3’ 
We ligated the β chain gene to zeta-2A and subcloned them into pBS II vector 
digested with BamHI and Apa I. We ended up with the following piece of 1078 bp that 
was confirmed correct by sequencing: 
 
 
 
 
 
4.2.1.6 Generation of HLA-DRA*0101 
 NCBI nucleotide search found the sequence for Homo sapiens HLA-DRA 
(GenBank Accession NM_019111 on May 5, 2003) mRNA with exons 2 and 3 coding 
Beta chain Zeta 2ABamHI ApaI
AatII
 62 
for the extracellular domains and exon 4 coding for the transmembrane domain and the 
cytoplasmic tail. cDNA produced from MGAR cells as described at 4.2.1.1 was used to 
isolated the DRA fragment. The extracellular and transmembrane domains of interest 
were flanked by ApaI and AatII restriction sites. The following set of primers was used 
for amplification of the two domains: 
 Forward primer: 5’-AATCCCGGGCCCATGGCCATAAGTGGAGTCCCTGTG 
 
 Reverse primer: 3’-CTCTTGACGTCAATCCCTTGATGATGAAGATGGTCCCAA 
  
 PCR amplification yielded a 736 bp product. This gene was subcloned into pBS II 
vector digested with the two enzymes after sequencing and checking for the correct 
sequence. 
 
4.2.1.7 Generation of synthetic ζ tail 
 Two zeta tails were required for the MBP-DR2-ζ construct, one linked to the α 
chain, the second linked to the β.  For the β chain, native ζ sequence was used. For the α 
chain, we chose to redesign the ζ tail by keeping the same amino acid sequence but 
changing the codons that determine each amino acid. This was to ensure that 
rearrangement between the two ζ chains would not occur during the production of 
retrovirus. Synthetic ζ was engineered as two sets of large oligos, one for the first half of 
the construct and the second one for the rest of the construct. The 3’ end of the first set 
and the 5’ end of the second set, respectively, had a PstI restriction site. The two sets are 
as follows: 
ApaI 
AatII 
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Set 1 - Forward primer: 5’-GGAGCGGATCCGACGTCCGCGTAAAATTTTCTCG 
 
TTCAGCTGATGCACCAGCTTATCAACAAGGACAAAATCAACTATACAATGAA 
CTGAACCTTGGTAGGCGTGAAGAATATGAC 
Reverse primer: 3’-TTTGTCCTTCTGCAGCTCGTTATAAAGTCCCTCTTGTGGA 
 
TTTTTTGCGACGTGGTTTACCTCCCATTTCTGGATCTCTTCCTCTACGTTTAAT
CTAG TACGTCATATTCTTCACGCCT 
Set 2 – Forward primer: 5’-AACGAGCTGCAGAAGGACAAAATGGCAGAAGCA 
 
TATTCAGAAATCGGAATGAAGGGAGAAAGAAGACGAGGTAAAGGCCATGAC
GGATTATAT 
Reverse primer: 3’-GACTACTCGAGTTATTACCTTGGAGGTAATGCTTGCATA 
 
TGTAAAGCATCATAAGTATCTTTTGTAGCCGTTGATAATCCTTGATATAACCG
TCATGGCC 
The two sets of primers were annealed and made double stranded using one PCR 
cycle (4 minutes denaturation at 94˚C, 1 minute annealing at 55˚C, 3 minutes extension at 
72˚C) and high fidelity Taq polymerase, followed by purification and digestion with the 
two sets of enzymes, BamHI – PstI and PstI – XhoI for the second one. The two pieces of 
the synthetic ζ gene were then subcloned into pBS II vector digested with BamHI and 
XhoI. The product was 354 bp long. 
This synthetic gene was then ligated together with the α chain and subcloned 
AatII BamHI 
PstI 
PstI 
XhoI 
 64 
again into pBS II vector digested with ApaI and XhoI. We ended up with a gene of 1090 
bp shown below that was confirmed correct by sequencing: 
 
 
 
 
 
4.2.1.8 Ligation into the final construct 
 We have avoided the inconvenience of cloning six genes of different sizes into a 
considerably large vector such as MSCV (6.825 Kb) by subcloning two genes at a time 
into a smaller vector, pBS II KS (+) of only 3 Kb. We ended up with three pieces of the 
final product: leader-MBP, beta-ζ-2A, and alpha-synthetic ζ of 185, 1078, and 1090 bp, 
respectively. We then subcloned the leader-MBP and the beta-zeta-2A into pBS II. This 
step yielded the following clone of 1263 bp, shown below:  
 
 
 
 
 
 We digested this new gene with EcoRI/ApaI and inserted it along with the alpha-
synthetic ζ one digested with ApaI/XhoI into MSCV retroviral vector cut with  
EcoRI/XhoI that includes an IRES linked to GFP. The whole leader-MBP-β-ζ-2A-α- 
synthetic ζ construct was 2.352 Kb. 
Alpha chain Synthetic zetaApaI XhoI
AatII
leader hMBP84-102EcoRI
NheI
Beta chain Zeta 2A ApaI
AatIIBamHI
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4.2.2 Design of humanized tailless MBP-DR2 construct 
This signaling deficient construct was produced in order to clarify the role of CR 
signaling for RMTC function.  
 
4.2.2.1 Generation of leader-MBP peptide 
We used the same leader-MBP peptide gene that we previously used for the tail-
bearing construct restricted by the same sites, EcoRI and BamHI (see 4.2.1.1 and 
4.2.1.2). 
 
4.2.2.2 Generation of HLA-DRB1*1501 
 We amplified the cDNA with the following set of primers, adding the same 
BamHI as for the previous construct, but changing the second site to an ApaI. The 
reverse primer was a large oligonucleotide that also contained the 2A sequence in a 
manner analogous to how we added 2A to the ζ chain in the MBP-DR2-ζ construct:  
 Forward primer: 5’-TCAGGCGGATCCGGGGACACCCGACCACGTTTCTTG 
 
Reverse primer: 3’-GCCATGGGCCCGGGATTTTCCTCCACGTCCCCGCATGTT 
 
AGAAGACTTCCCCTGCCCTCGGCTCTGCGAGGGGGCAGGGCCTGCATGTGAA
G 
 Similar to the other genes, the beta 2A gene was also sequenced and subcloned 
into pBS II vector. 
 
BamHI 
Apa I 
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4.2.2.3 Generation of HLA-DRA*0101 
 We amplified the cDNA with the following set of primers, adding an ApaI 
restriction site to link it to the HLA-DRB1*1501 construct, but also an XhoI at the 
terminus to link it to the MSCV vector since we removed the synthetic zeta gene. 
 Forward primer: 5’-AATCCCGGGCCCATGGCCATAAGTGGAGTCCCTGTG 
 
 Reverse primer: 3’-TACTACTCGAGTTATTACAGAGGCCCCCTGCGTTCTGC 
  
This gene was subcloned into pBS II vector sequenced to confirm it. 
 
4.2.2.4 Ligation into the final construct 
 Similar to the MBP-DR2-ζ construct, we chose to subclone leader-MBP with the 
beta 2A gene first to circumvent possible cloning difficulties that might occur in a four-
way ligation. The new product, leader-MBP-beta 2A (shown below – 742 bp) was 
subcloned into the pBS II vector. 
 
 
 
 
This new gene was then digested with EcoRI and ApaI and then cloned into the 
final vector, MSCV-IRES-GFP, along with the ApaI/XhoI-cut alpha gene of 736 bp, 
yielding a product of 1.8 Kb.  
 
 
XhoI 
 
ApaI 
 
leader hMBP84-102EcoRI
NheI
β chain-2A ApaI
BamHI
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4.2.3 Generation of retrovirus-producing cell lines 
 Retroviruses are small oncoviruses with an outer envelope and an inner core 
containing negative double-stranded RNA responsible for genetic information. Since 
retroviruses can infect living cells and insert DNA into the genome, they have been 
converted into gene delivery systems and are able to transduce a wide variety of cell 
types from different species. For safety reasons, the retrovirus must be able to infect 
target cells but not replicate. This has been accomplished by replacing the coding region 
that gives rise to essential viral proteins with the gene of interest to be transferred. This 
replication-defective virus cannot make the proteins needed for subsequent rounds of 
replication, but the retrovirus can still enter into the cells and integrate the viral genome 
in the DNA of the cell. To produce recombinant retroviruses, the env, gag, and pol 
proteins (still needed for production of new virus) are provided in trans by separate 
constructs transfected into retroviral packaging cells. 
 
4.2.3.1 Generation of MBP-DR2-ζ and MBP-DR2 retroviruses 
In order to generate the two retroviral ecotropic vectors we used two helper 
plasmids encoding encoding the gag-pol and env proteins (pEQ.PAM-E and pVSVg) and 
a plasmid containing the MSCV retroviral vector including the CR constructs.  We used 
293 T cells as packaging cells for an initial transient transfection. The virus supernatant 
produced by these cells was then used to infect GP+E86 cells, which were maintained as 
stable viral producers and from which retrovirus used to transfect T-cells was harvested. 
We followed the following protocol (75):  
Materials: 
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293 T cells and GP+E86 cells 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum 
(FCS) and penicillin-streptomycin-glutamine (PSG) 1% 
pEQ.PAM-E plasmid  
pVSVg plasmid 
MBP-DR2-ζ/MBP-DR2 plasmid 
Calcium chloride CaCl2 2.5M 
2X Hepes Phosphate Buffered Saline (HPBS) pH 7.12 
Method: 
24-hours prior to transfection, 2x106 (or 4x106 the day of transfection) 293 T cells 
were plated on a 10 ml tissue-culture treated Petri dish. On the day of transfection, four 
hours prior to the procedure, the medium was changed with fresh complete DMEM. At 
the time of transfection, cells were approximately 70% confluent. DNA mix was prepared 
using 4 µg pEQ.PAM-E and 2 µg pVSVg  and 4µg MBP-DR2-ζ/MBP-DR2 plasmid, 50 
µl 2.5M CaCl2 and adjusted to 500 µl with distilled water at room temperature (RT). This 
mix was then added to 500 µl HPBS dropwise while vortexing and incubated 1 minute at 
RT. The whole mixture was added onto 293 T cells and incubated for 16 hours at 37˚C. 
The next day the plates were washed with prewarmed phosphate buffered saline (PBS) 
twice and new complete DMEM was added. 3x105 GP+E86 cells were plated in a 10 ml 
dish. 24-hours later, the medium from 293T cells was replaced, spun at 3000 rotations per 
minute (RPM) for 5 minutes in a centifuge with rotor and then the supernatant was used 
to infect GP+E86 cells twice a day, adding 8 µg/ml polybrene to facilitate binding and 
entry of the retrovirus. The GP+E86 cell line was used to produce retroviral supernatant 
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which was then used to transduce 4G4 T cell hybridoma and activated primary murine T-
cells. It is recommendable that the GP+E86 cells be frozen in freezing mix (EHAA 
medium with 20% heat inactivated FCS and 10% dimethyl sulfoxide (DMSO) and kept at 
-80˚C as soon as the transfection has been finished. Since they are stably transfected with 
retrovirus, they can be thawed out and frozen again multiple times. After thawing, 
GP+E86 cells were washed once in HBSS medium and plated onto large or medium 
tissue culture-treated flasks. Retroviral supernatant was collected daily and the medium 
was replaced until the cells were completely confluent.  
 
4.2.3.2 Retroviral transduction of 4G4 T-cell hybridoma  
GP+E86 cells previously transfected with either MBP-DR2-ζ CR (GP+E86-MBP- 
DR2-ζ) or MBP-DR2 CR (GP+E86-MBP-DR2) were thawed out from the liquid nitrogen 
tank, washed once with 1x Hanks’ balanced salt solution (HBSS, Gibco, Carlsbad, CA), 
and cultured in 75 or 150 ml culture-treated flanks. Viral supernatant was collected at 24 
hours and spun at 3000 rpm for 5 minutes. 4x106 4G4 T-cell hybridoma were added per 
well in a 6-well plate and 2 mls of retroviral supernatant and 8 µg/ml polybrene were 
added, and the cells were spun at1800 rpm for 90 minutes in a centrifuge with rotor. The 
procedure was repeated twice for a better yield of GFP+ cells.  
 
4.2.3.3. Flow cytometry of retrovirally-transduced cells 
 To check for HLA class II expression, transduced 4G4 cells were resuspended in 
FACS buffer (PBS with 1% BSA and 0.1% sodium azide (NaN3, Sigma) and incubated 
30 min on ice with primary phycoerythrin-conjugated (PE) anti-human HLA-DR 
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antibody (Becton Dickinson, Franklin Lakes, NJ) at the concentration recommended by 
the supplier. The cells were then washed and resuspended in FACS buffer and analyzed 
using a FACSCalibur (BD Biosciences) and CellQuest software. CR-transduced 
hybridoma were then flow cytometric sorted for GFP+ on a MoFlo high-speed cell sorter 
(DakoCytomation) (courtesy of Dr. Richard Cross, PhD, St. Jude Children's Research 
Hospital). 
  
4.2.3.4 Retroviral transduction of primary murine T-cells 
  Lymph nodes and spleen from C57BL/6 mice or OT-1 mice (transgenic for CD8+ 
cells) were harvested and processed into a single cell suspension by crushing through a 
40-µm nylon filter. Red blood cells were lysed with Gey’s solution (7.0 g/l NH4Cl, 0.37 
g/l KCl , 0.3 g/l Na2HPO4.12H2O, 0.024 g/l KH2PO4, 1.0 g/l glucose, 10.0 mg/l phenol 
red, 8.4 mg/l MgCl2.6H2O, 7.0 mg/l MgSO4.7H2O, 6.8 mg/l CaCl2 and 45 mg/l NaHCO3) 
and the lymphocytes were cultured in 6-well plates and stimulated with 2 µg/ml purified 
mouse anti-CD3ε and 2 µg/ml anti-CD28 antibodies (Pharmingen, San Diego, CA) or 2 
µg/ml Concanavalin A (ConA) overnight. After 24 and 48 hours, the media was carefully 
removed and 2 mls/well of viral supernatant was added along with 8 µg/ml polybrene and 
sorted for GFP expression by flow cytometry. GFP+ cells were re-fed and split into 6-
well plates when they reached a high density. They were also sorted for GFP+ and on day 
10-12, the cells were restimulated with 2 µg/ml ConA and irradiated (4,000 rad) 
syngeneic splenocytes.  
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4.2.4 Ob and 6F11 target hybridoma cell lines 
 
4.2.4.1 Stimulation of Ob hybridoma with hMBP84-102 peptide 
 105 Ob and 6F11 cells were incubated overnight with four different 
concentrations of purified hMBP84-102 peptide on a 96-well round-bottom plate in 
complete Bruff medium (EHAA or Click’s medium enriched with 10% FCS, 1% 
Penicillin-Streptomycin-Glutamine (PSG), and 4.2 µl 2-mercaptoethanol per 1,000 ml 
medium). Irradiated (20, 000 rad) MGAR cells were used as antigen presenting cells. 24-
hours later, 60 µl of supernatant was removed and submitted for IL-2 secretion analysis 
by Multiplex (Bio-Rad, Hercules, CA).  
 
4.2.4.2 Stimulation of Ob hybridoma with mouse anti-humanVβ2 antibody 
A 96-well flat bottom plate was coated with 10 µg/ml purified rat anti-mouse IgG 
(Jackson Immunoresearch Laboratories, Inc., West Grove, PA) and incubated at 4˚C 
overnight. 24-hours later, the plate was washed three times with HBSS solution and 
coated with 50 µg/ml mouse anti-human TCR Vβ2 monoclonal antibody (Immunotech, 
Warrenale, PA) either overnight at 4˚C or for two hours at 37˚C. The plate was washed 
again and 105 Ob or 6F11 cells were added. 24-hours later 60 µl of supernatant was 
removed and submitted for IL-2 secretion. 
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4.2.5 Stimulation of TCR/DR2 T lymphocytes 
  
4.2.5.1 Stimulation of TCR/DR2 T lymphocytes with hMBP84-102 peptide 
5x105 cells from lymph nodes or splenocytes of double transgenic mice were 
cultured in 96-well flat-bottom plates without antigenic peptide or with peptide in 
different concentrations and irradiated splenocytes from humanized DR2 transgenic mice 
(denoted as Fug5). After 72 hours of culture, the cells were pulsed with 1 µCi of 
[3H]thymidine and harvested on filtermats16 hours later. All samples were analyzed in 
triplicates. 
 
4.2.5.2 Stimulation of TCR/DR2 T lymphocytes with EL4-MBP-DR2 cells 
 2x106 T-cells from lymph nodes or splenocytes of transgenic mice were 
stimulated with 4x106 irradiated (20,000 rad) EL4-MBP-DR2 antigen-presenting cells 
(EL4 thymoma cells transduced with the tailless MBP-DR2 construct) and the same 
number of irradiated feeders. The cells were grown in complete Bruff medium with  
10 U/ml recombinant IL-2 and split every other day. We have also used this procedure to 
build an antigen-specific cell line by re-stimulating them in the same conditions on day 
ten, using Con A as a mitogen.  
 
4.2.6 Stimulation of RMTC with HLA-DRB antibody  
The plate-bound antibody stimulation was set up as described at 4.2.4.2. Briefly, 
transduced 4G4 RMTC were stimulated with three different concentrations of plate-
bound mouse anti-human HLA-DR2 antibody or control goat anti-mouse IgG. 24-hours 
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later, 60 µl of supernatant was removed and submitted for IL-2 secretion analysis by 
Multiplex. 
 
4.2.7 IL-2 secretion by RMTC in response to recognition of Ob hybridoma 
 5x105 4G4 hybridoma transduced with MSCV and MBP-DR2-ζ were cocultured 
in three different ratios with Ob or 6F11 target hybridoma in a 96-well round bottom 
plate for 8 hours. The cells were spun, the medium was replaced, and Brefeldin A (BFA, 
Epicentre Technologies) was added for 6 hours at 37˚C and 5-10% CO2. The cells were 
spun again at 4˚C and then washed with staining wash buffer (SWB; 1x PBS, 2% FBS, 
0.1% NaN3) and BFA 10µg/ml. The primary surface antibody (mouse anti-human Vβ2 
PE-conjugated) diluted in SWB+BFA was added and the plate was then incubated on ice 
for 20 minutes, then washed with PBS+BFA twice and resuspended in the same mix. The 
cells were then fixed with 2% formaldehyde in PBS for 20 minutes at RT, washed and 
incubated in permeabilization buffer (SWB + 0.5% saponin) for 10 minutes at RT. The 
cells were then incubated with the APC (Allophycocyanin)-conjugated rat anti-mouse IL-
2 monoclonal antibody (Becton Dickinson) for 30 minutes on ice, followed by a wash 
with PBS, and resuspension in SWB. Flow cytometric analysis was performed after 
gating on the double positive, APC+ (on FL4 axis)/GFP+ (on FL1 axis) cells or 
alternately, on APC+ (on FL4 axis)/Vβ2+ (on FL2 axis) cells. This way we can identify 
the cells that secrete IL-2 (featured by APC staining) by gating on either FL1/FL4 (GFP+ 
cells secreting IL-2) or FL2/FL4 (Ob hybridoma secreting IL-2). 
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4.2.8 IFN-γ secretion by RMTC in response to recognition of Ob hybridoma 
 5x105 Ob hMBP84-102-specific hybridoma or 6F11 control cells were cocultured 
with RMTC transduced with MSCV, MBP-DR2-ζ, and MBP-DR2 chimeric receptors for 
24 hours. 60 µl of supernatant was then removed and submitted for cytokine secretion 
analysis by Multiplex. 
 
4.2.9 Proliferation of RMTC in response to stimulation by Ob hybridoma 
 5x104 GFP+-sorted CD8+-transduced RMTC cells were incubated with different 
ratios of irradiated Ob or 6F11 hybridoma and syngeneic feeders on a 96-flat bottom 
plate. After 72 hours, the cells were pulsed with 1µCi [3H] thymidine and harvested after 
16 hours. Proliferation was measured by liquid scintillation counting of incorporated [3H] 
thymidine. The samples were analyzed in duplicates and plotted as mean ± 1 stdev.  
  
4.2.10 Cytolysis of target cells by RMTC 
 
4.2.10.1 Cytolysis of Ob target hybridoma by RMTC assayed by radioactive chromium 
(Cr) release 
4x106 Ob hybridoma specific for human MBP84-102 peptide or 6F11 control 
hybridoma specific for MBP89-101 were incubated with 200 µCi 51Cr for 30 minutes at 
37˚C with intermittent shaking. After half an hour, the cells were washed three times with 
PBS saline solution and cocultured in different effector to target ratios with CD8+-RMTC 
transduced with MBP-DR2-ζ, MBP-DR2, or MSCV vector for 4 hours on a 96-well 
round bottom plate. All cell combinations were set up as triplicates. Target cells in 
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medium only were also set for controls. Labeled antigenic targets are recognized and 
lysed by RMTC, releasing radioactivity into the supernatant. 20 µl TritonX (Sigma-
Aldrich, St Louis, MO) was added to 51Cr-labeled Ob hybridoma (control wells) and 
served as a positive control for maximal release of radioactive Cr. Spontaneous lysis 
(control 51Cr) was estimated by the release of radioactive Cr by Ob hybridoma alone.  
 After incubation at 37˚C, the plate was centrifuged and 100 µL supernatant was 
harvested and counted. We used the formula below to calculate the percent of specific 
cytolysis from the release of 51Cr: 
 (Experimental 51Cr – control 51Cr)/(maximal 51Cr – control 51Cr) x100 
 
4.2.10.2 In vitro cytolysis of primary MBP-DR2-specific cells by RMTC 
  105 T-cells/well from TCRxDR2 double transgenic (DTG) or TCRxDR2xhCD4 
triple transgenic (TTG) mice were cocultured with CD8+ RMTC at different ratios 
overnight in a 96-well round bottom plate. The next day, the plate was centrifuged and 
cells were double stained with the mouse anti-human Vβ2.1 antibody (PE) and rat anti-
mouse CD4+ or CD8+ antibody (APC). After 30 minutes incubation on ice, the cells were 
washed and resuspended in SWB. In order to find out the absolute number of target cells 
left after overnight cytolysis, we used TruCOUNT assay and added TruCount high 
control fluorescent beads (BD Bioscience, San Jose, CA) at a final concentration of 2000 
beads/sample. These beads were used as markers to guarantee that equal fractions of each 
sample were enumerated, thus allowing quantitative comparison of the number of events 
and eliminating the variability between samples. The absolute number of cells in the 
sample can be determined by normalizing to the number of acquired beads. 
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FACSCaliburTM was used with forward (FCS) and side scatter (SSC) set in a logarithmic 
mode. TruCount beads were gated in a FCS/SSC plot and analysis was stopped when 500 
beads were counted. We then ran the sample tubes and analyzed the double positive 
hVβ2.1+CD4+ or hVβ2.1+CD8+ cells after gating and counting 500 beads.  
 
4.2.10.3 In vitro cytolysis of primary MBP-DR2-specific T-cells by RMTC detected by 
stimulation with EL4-MBP-DR2 cells  
 This experiment was set up similarly to 4.2.10.2. Unlike the previous experiment, 
we chose not to directly analyze the residual cells after the overnight coculture of the two 
cell types, but instead we added 2x105 EL4-MBP-DR2 antigen-presenting cells or control 
EL4 cells at the time of the culture, for five days. On day five we stained each well with 
mouse anti-human Vβ2.1 and rat anti-mouse CD4+ and CD8+ antibodies and analyzed the 
residual double positive cell counts by quantitative flow cytometry. 
 
4.2.10.4 Cytolysis of target DTG cell lines by RMTC 
 105 double or triple transgenic cell lines (obtained as described in 4.2.5.2) were 
cocultured with MSCV retroviral vector control, MBP-DR2-ζ, or MBP-DR2 RMTC in a 
96-well round bottom plate for six hours at four different ratios. After 6 hours, we stained 
the cells as described in 4.2.10.2 and evaluated the number of residual hVβ2.1+CD4+ and 
hVβ2.1+CD8+ cells by quantitative FACS. 
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4.3 Results 
 
4.3.1 Design of chimeric receptors  
 In order to specifically target pathologic, hMBP-specific T lymphocytes, we 
engineered two chimeric receptors: MPB-DR2-ζ and MBP-DR2. The first CR included 
the extracellular and transmembrane domains of the human MHC class II beta chain 
DRB1*1501 linked to the human MBP peptide epitope 84-102 and the ζ cytoplasmic 
domain of the TCR. A 2A sequence from TaV connected this part of the construct with 
the human MHC class II alpha chain DRA*0101 paired with the ζ cytoplasmic tail of 
TCR. The whole gene was subcloned in MSCV retroviral expression vector that contains 
an IRES site and the GFP gene (Figure 4-1). In parallel we designed a tail-deficient CR 
that lacked any signaling moiety from the TCR (Figure 4-2).  
 
4.3.2. Transfection of CRs into transient and permanent viral-producing cell lines 
 Transfection of both retroviruses had a good yield in both 293T and GP+E86 cells 
(Figures 4-3 and 4-4). The latter cell line was used to produce retroviral supernatant 
which was then used to transduce 4G4 T-cell hybridoma and activated murine T-cells.  
 
4.3.3 Transduction of 4G4 T-cell hybridoma and primary murine T-cells   
 Transduction of both 4G4 T-cell hybridoma and primary murine T-cells had a 
good yield, although we noticed a difference between the efficiency of transduction in 
4G4 hybridoma and primary T lymphocytes. 4G4 cells transduced with the ζ-bearing C 
showed an equivalent surface expression of the receptor compared to the ζ-deficient CR, 
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Figure 4-1. MSCVII-GFP-MBP-DR2-ζ construct. The immunodominant epitope of the human myelin basic protein 
was genetically linked to the extracellular and transmembrane domains of MHC class II β chain chain and human 
cytoplasmic TCR ζ chain. This was then paired with the extracellular and transmembrane domains of MHC class II α 
chain and another cytoplasmic signaling tail. The 2A sequence from FMDV was inserted between the DRB β and α 
chain to provide equal amounts of the bicistronic message. 
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Figure 4-2. MSCV II-GFP-MBP-DR2 construct. This construct is similar to MSCV II-GFP-MBP-DR2-ζ 
construct (in Figure 4-1) with the exception of the ζ cytoplasmic signaling tail. 
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Figure 4-3. Transient retroviral transfection in 293T cells. 293T cells were transiently 
transfected with retrovirus according to the methods. The percentage represents the GFP+ 
cells. FL1 axis shows uncompensated GFP+ cells. Top center: 293T cells transfected with 
MSCV (empty virus). Bottom left: 293T cells transfected with MBP-DR2-ζ construct. 
Bottom right: 293T cells transfected with MBP-DR2 construct.
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Figure 4-4. Retroviral transfection in GP+E86 cells. GP+E86 cells were transfected 
with retroviral supernatant from 293T cells according to the methods. The percentage 
represents the GFP+ cells. FL1 axis shows uncompensated GFP+ cells. Top center: GP+E 
cells transfected with MSCV (empty virus). Bottom left:GP+E cells transfected with 
MBP-DR2-ζ construct. Bottom right: GP+E cells transfected with MBP-DR2 construct. 
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whereas transduction in murine T lymphocytes showed an approximately 30% increase in  
the surface expression levels of MBP-DR2 CR compared with MBP-DR2-ζ (Figures 4-5 
and 4-6). 
 In conclusion, there’s a clear difference between the transduction efficiency in 
hybridoma compared to activated T-cells. Hybridoma are very uniform, clonally 
expanded cells that would exhibit the same ability to harbor a retrovirally-transduced 
gene. The intracytoplasmic signaling tail renders the CR capable of signal transduction 
and therefore, primary activated T-cells transduced with the tail-bearing CR will 
internalize the surrogate receptor, leading to a decreased surface expression of the CR. 
Removal of the signaling tail restores the surface expression of the CR to almost the same 
levels as MSCV control. 
 
4.3.4 Specificity of Ob hybridoma 
 Before we proceeded to use Ob hybridoma as target cell lines, we first needed to 
ensure their antigenic-specificity by testing their response to stimulation with peptide and 
the mouse anti-human Vβ2 antibody. 
 
4.3.4.1 Stimulation of Ob hybridoma with hMBP84-102 peptide 
To verify the specificity of Ob hybridoma for hMBP, we stimulated the cells with 
different concentrations of antigenic peptide. The Ob hybridoma secreted IL-2 in 
response to peptide stimulation. The amount of IL-2 secreted by the cells was directly 
proportional to the amount of antigenic peptide used to stimulate the cells. Control 6F11 
hybridoma did not show any response to stimulation with hMBP restricted by HLA-DR2 
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Figure 4-5.  Expression of HLA-DR2 on 4G4 T-cell hybridomas  transduced with chimeric receptors. MSCV 
retroviral vector control, ζ-bearing, and ζ-deficient CRs were transduced into 4G4 TCR-/- hybridomas. The efficiency of 
transduction is shown by the amount of GFP which represents the surface expression level of the chimeric receptors. The 
cells were stained with mouse anti-human HLA-DR2 antibody and then analyzed by FACS. Left panel: MSCV-transduced 
4G4 T cells. Middle panel: MBP-DR2-ζ-transduced 4G4 T cells. Right panel: MBP-DR2-transduced 4G4 T cells. 
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Figure 4-6.  Expression of HLA-DR2 on primary murine  CD8+ T-cells  transduced with chimeric receptors. MSCV 
retroviral vector control, ζ-bearing, and ζ-deficient CRs were transduced into primary CD8+ T-cells. The efficiency of 
transduction is shown by the amount of GFP which represents the surface expression level of the chimeric receptors. The cells 
were stained with mouse anti-human HLA-DR2 antibody and then analyzed by FACS. Left panel: MSCV-transduced  T-cells. 
Middle panel: MBP-DR2-ζ-transduced  T-cells. Right panel: MBP-DR2-transduced T-cells. 
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(Figure 4-7 upper panel).  
 
4.3.4.2 Stimulation of Ob hybridoma with mouse anti-humanVβ2 antibody 
 Ob hybridoma are specific for hMBP84-102 restricted by HLA-DR2 and they 
stain for hVβ2 antibody. Upon stimulation with plate-bound mouse anti-human Vβ2, Ob-
specific, but not 6F11 control cells responded to this stimulation by IL-2 secretion 
(Figure 4-7 lower panel). 
 In conclusion, we hereby proved that Ob hybridoma constitutes a clonal 
population of cells specific for hMBP84-102 peptide and they respond stimulation with 
either the peptide or the specific Vbeta antibody by proliferation. 
 
4.3.5 Specificity of T lymphocytes from TCR/DR2 transgenic mice 
 
4.3.5.1 Stimulation of TCR/DR2 T lymphocytes with hMBP84-102 peptide 
To reproduce previously published data, we stimulated T lymphocytes from 
double transgenic TCRxDR2 mice with hMBP84-102. We did not obtain consistent 
results, and the proliferative response of T-cells proved extremely variable with different 
mice and experiments. T-cells removed from the lymph nodes of some of the mice 
responded very well to peptide stimulation, while others did not (Figure 4-8). 
 
4.3.5.2 Stimulation of TCR/DR2 T lymphocytes with EL4-MBP-DR2 cells 
Considering the results from the previous experiment, we searched for alternative 
ways of stimulating antigen-specific cells from DTG mice. Specifically, because we 
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Figure 4-7. Ob cells respond to stimulation by producing IL-2. Ob and control 6F11 
hybridoma were stimulated with different dilutions of hMBP peptide (upper panel) or 
mouse anti-human TCR Vβ2 (lower panel) antibody and secretion of IL-2 was assayed 
after 24 hours. Only Ob hMBP-specific cells, but not 6F11 control cells responded to 
stimulation by the secretion of IL-2. 
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Figure 4-8. Proliferation of TCR/DR2 cells in response to hMBP peptide. T-cells 
from lymph nodes of TCR/DR2 mice were stimulated with different concentrations of 
peptide and 72 hours later 1µCi [3H] thymidine was added to each well. Proliferation was 
measured by liquid scintillation counting. Top figure: in this particular experiment, the 
transgenic T-cells proliferated robustly in response to peptide stimulation. Bottom figure: 
in this experiment, the transgenic T-cells did not respond to peptide stimulation. 
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suspected that the low expression levels of DR2 gene on B cells from humanized class II 
transgenic mice (Fug5) were impeding the proper stimulation of hMPB-specific cells, we  
 we tested the use for EL4 thymoma cells transduced with the MBP-DR2 tail-deficient 
construct as a stimulus. This way the antigen-specific cells would undergo a proper 
stimulation, but will not suffer the effects that the tail-bearing CR would provide. We 
showed that EL4-MBP-DR2 cells, though not EL4 cells alone, stimulate lymph node or 
spleen-derived T-cells from DTG or TTG mice due to expression of hMBP-DR2 (Figure 
4-9).  
 
4.3.6 Stimulation of RMTC by HLA-DRB antibody  
 Since RMTC are transduced with CRs containing the DR2 gene, we wanted to 
first test the ability of our CRs to be stimulated by the specific MHC class II antibody. 
We used 4G4 T cell hybridoma expressing the CRs. Upon stimulation with the plate-
bound mouse anti-human DR2 antibody, only 4G4-MBP-DR2-ζ cells responded by IL-2 
secretion. This demonstrates that the chimeric receptor bearing the signal transduction 
domain is the only one able to transmit a functional signal and that deletion of the ζ 
cytoplasmic domain impairs this ability (Figure 4-10).  
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Figure 4-9.  CD4+ and CD8+ TCR/DR2 cells respond to stimulation by EL4-MBP- 
DR2. CD4+ (top panel) and CD8+ (bottom panel) cells from lymph nodes and spleens of 
TCR/DR2 mice were sorted and stimulated with hMBP peptide, EL4 control, or EL4-
DR2 antigen-presenting cell lines (EL4-MBP-DR2) for 72 hours. Proliferation was 
assayed by [3H]thymidine incorporation.  
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Figure 4-10. Stimulation of RMTC by anti-HLA-DR2 antibody. 4G4 T-cells were 
transduced with MBP-DR2-ζ, MBP-DR2, and MSCV control retrovirus and cultured 
overnight on an anti-DR2 antibody-coated plate. 24-hours later, 60 µl supernatant was 
removed and checked for secretion of IL-2. 4G4-MBP-DR2-ζ cells showed exclusive 
secretion of IL-2. 
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4.3.7 Specific recognition and stimulation of target cell lines by MBP-DR2-ζ-bearing 
RMTC   
 
4.3.7.1 Recognition of cognate TCR by RMTC 
Having proven that the MBP-DR2-ζ-RMTC can be specifically stimulated by the 
anti-DR2 antibody, we next wanted to test the ability of the RMTC to specifically  
recognize cognate TCR on the surface of Ob target hybridoma and transmit a signal in 
response to this recognition. Upon coculture with irradiated hMBP84-102/DR2-specific 
Ob hybridoma but not control MBP89-101/I-As-specific 6F11 hybridoma, MBP-DR2- 
ζ-transduced 4G4 T-cells secreted IL-2 detectable by flow cytometry after 
intracytoplasmic staining. Although this approach does not provide information about the 
amount of IL-2 secreted, we were nevertheless able to identify the specific interaction 
that yielded this cytokine (Ob hybridoma and 4G4-MBP-DR2-ζ cells) and the specific 
cell type that produced it (4G4-MBP-DR2-ζ cells). This was an important piece of 
information since both the Ob and RMTC cells can produce IL-2 and it proved that the 
RMTC were specifically responding to cognate TCR stimulation (Figure 4-11). 
 To analyze similar recognition by CR-transduced primary CD8+ T-cells, we 
stimulated the MBP-DR2-ζ, MBP-DR2, and MSCV control CTL RMTC with Ob or 
6F11 control and quantitated the secretion of IFN-γ. Hybridoma do not produce this 
cytokine, whereas primary T-cells do. This shows that the only cell type producing INF-γ 
would be the tail-bearing RMTC (Figure 4-12).  
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Figure 4-11. Intracellular IL-2 production by 4G4-MBP-DR2-ζ cells. Ob and 6F11 
target cells were cocultured with 4G4-RMTC for 8 hours and the number of cells 
producing IL-2 was assessed by flow cytometry. 4G4 cells transduced with the ζ-bearing 
chimeric receptor secreted IL-2 in response to stimulation by Ob specific, but not control 
6F11 hybridoma. 
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Figure 4-12. IFN-γ secretion by MBP-DR2-ζ RMTC stimulated by Ob hybridoma. 
We cocultured target (Ob or 6F11 cells) with RMTC effector cells at 4 different ratios. 
IFN-γ was secreted by MBP-DR2-ζ CD8+ T-cells (but not MBP-DR2 CD8+ T-cells or 
MSCV retroviral vector control cells) upon recognition of cognate TCR on Ob, but not  
control 6F11 hybridoma. 
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4.3.7.2 Proliferation of MBP-DR2-ζ RMTC in response to stimulation with Ob 
hybridoma  
Irradiated Ob hybridoma were capable of inducing proliferation of CD8+ MBP-
DR2-ζ RMTC at all tested ratios of responders to target cells (Figure 4-13). This 
experiment, along with the previous ones, proved that RMTC can recognize antigen-
specific T-cells upon cognate TCR-CR interaction and this recognition induces the 
RMTC effector functions, including cytokine secretion and proliferation.  
 
4.3.8 Cytolysis of target cells by RMTC 
 The ultimate goal that the RMTC were designed for is the specific cytolysis of 
antigen-specific cells or cell lines. We used two types of target cells: Ob or 6F11 control 
hybridoma, and naïve or activated T-cells from TCR/DR2 transgenic mice. 
 
4.3.8.1 Cytolysis of Ob target hybridoma by RMTC 
The cytolytic activity of genetically modified CD8+ RMTC was evaluated by the 
release of 51Cr after four hours of coculture of RMTC with 51Cr-labeled Ob or 6F11 
hybridoma. CD8+ RMTC bearing the ζ-chimeric receptor were capable of specifically 
killing over 70% of antigen-specific target Ob hybridoma, but did not kill 6F11 controls 
even at effector:target ratio as low as 1:1 cells. Tailless MBP-DR2 RMTC and MSCV 
control T-cells were not able to kill either targets. This shows that RMTC bearing the ζ-
CR are able to specifically and efficiently kill hMBP84-102/DR2 target Ob hybridoma, 
whereas removal of intracytoplasmic signaling tail renders RMTC unable to perform 
their killing function (Figure 4-14). 
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Figure 4-13. Proliferation of CD8+ MBP-DR2-ζ RMTC in response to Ob 
hybridoma. Irradiated Ob or control 6F11 hybridoma were cocultured in different ratios 
with CD8+ RMTC and on day 3, [3H]thymidine was added and liquid scintillation 
counting was performed 24 hours later. At any given ratio, Ob hybridoma could only 
stimulate the proliferation of MBP-DR2-ζ-RMTC, but not the tailless CR-transduced T-
cells or MSCV retroviral vector-transduced cells. 
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Figure 4-14. Cytolysis of Ob hybridoma by CD8+-MBP-DR2-ζ RMTC. Ob hMBP-
specific or control 6F11 hybridoma were labeled with 51Cr and cocultured with RMTC 
for four hours. Specific cytolysis was calculated based on chromium release from the 
dead target cells. ζ-bearing CR-transduced cells were shown to have an exclusive and 
potent cytolytic activity against MBP-DR2-specific Ob hybridoma, but not control 6F11 
cells.  
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4.3.8.2 Cytolysis of primary antigen-specific T-cells by RMTC 
 Based on the ability of RMTC to kill Ob peptide-specific hybridoma, we 
hypothesized that the same RMTC would also display cytolytic activity against primary 
antigen-specific T-cells. The results challenged our hypothesis: although ζ-bearing 
RMTC did indeed kill Ob hybridoma, they failed or poorly killed naïve T-cells from 
DTG or TTG mice and with very little difference in the cytolytic abilities of the MBP-
DR2-ζ, MBP-DR2, and MSCV control transduced RMTC (Figure 4-15). A possible 
explanation would be the fact that, although the residual cells were hVβ2+, this does not 
constitute a direct indication of their antigenic specificity. Indeed, published data using 
ELISPOT analysis has shown only 0.5% of T-cells in TCR/DR2 double transgenic mice 
respond to hMBP84-102 (87). Therefore, we found an alternate approach to avoid 
stimulation with peptide by stimulating T-cells from these mice with the DR2+ antigen-
presenting cell line. 
 
4.3.8.3 Cytolysis of primary antigen-specific T-cells cells by RMTC detected by 
stimulation with DR2+ antigen-presenting cell line 
 Since primary, naïve antigen-specific cells from DTG animals could not be killed 
by RMTC probably due to the low number of hMBP84-102-specific cells, we used a 
different approach to detect residual hMBP-specific T-cells by stimulating target cells 
with DR2+ antigen-presenting cells (EL4-MBP-DR2) as described to selectively expand 
surviving antigen-specific T-cells. Analysis of residual target cells on day five of 
stimulation with the hMBP-presenting cell line identified a significantly lower number of 
peptide-specific cells when they were cocultured with MBP-DR2-ζ RMTC as opposed to 
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Figure 4-15. CD8+ RMTC show limited cytolysis of naïve TCR/DR2 cells from 
double transgenic (DTG) mice. T-cells from TCR/DR2 DTG mice were cocultured with 
RMTC in three different ratios overnight. The next day the cells were stained with anti-
human Vβ2 and anti-mouse CD4+ or CD8+ antibody. TruCount beads were added for 
quantitative assessment of the residual antigen-specific cells. RTMC were not able to 
efficiently kill primary, hMBP-specific T-cells. Upper panel: overnight cytolysis of CD4+ 
DTG cells by RMTC; lower panel: overnight cytolysis of CD8+ DTG cells by RMTC. 
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the number of target cells cocultured with MSCV control or tailless RMTC (Figures 4-16 
and 4-17). This leads to two conclusions. The first one is that, by day five after 
stimulation, the antigen-specific T-cells would undergo clonal expansion, whereas the 
non-antigen-specific cell would die. The second conclusion is that the significantly lower 
number of residual CD4 and CD8 antigen-specific cells when naïve target cells were 
cocultured with MBP-DR2-ζ CTL is due to killing by CTL as opposed to expansion of 
target cells were cocultured with MBP-DR2 or MSCV control CTL.  
Surprisingly, both CD4+ and CD8+ target cells from TCR/DR2 transgenic animals 
showed sustained proliferation in response to antigenic stimulation. Human MBP peptide 
is presented by HLA class II, DR2 gene. The fact that not only CD4 T-cells, but also CD8 
T-cells respond to this peptide by proliferation contradicts the dogma of immunology that 
CD4 T-cells would recognize antigens presented on an MHC class II molecule, whereas 
CD8 T-cells would recognize antigens complexed with MHC class I (92). This accounts 
for the coreceptor independence of CD8+ antigen-specific cells from TCR/DR2 
transgenic mice and explains their proliferation in response to peptide stimulation. 
 
4.3.8.4 Cytolysis of target DTG cell lines by RMTC 
 Knowing that peptide-specific cells from DTG mice can be expanded with the 
DR2+ antigen-presenting cell line, we were interested in determining whether we could 
produce hMBP-specific T-cell lines and whether the RMTC could similarly kill these cell 
lines. CD4+ and CD8+ hMBP-specific target cell lines were grown as described in 
Materials and methods (paragraph 4.2.5.2) and cocultured with RMTC. Only the CD4+ 
MBP-specific cell line was efficiently killed by MBP-DR2-ζ RMTC, whereas none of the 
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Figure 4-16. Cytolysis of primary CD4+ DTG target cells by RMTC measured by 
stimulation of residual MBP-DR2-specific T-cells. T lymphocytes from DTG mice 
TCR/DR2 were cocultured with therapeutic cells or MSCV retroviral control in three 
different ratios in the absence or presence of DR2+ antigen-presenting cell line (EL4-
MBP-DR2) for five days. At the end of the fifth day, the residual cells were stained with 
hVβ2 and mCD4 antibodies and quantitative FACS analysis was performed. We found a 
considerably lower number of residual CD4+ peptide-specific cells when these were 
cocultured with MBP-DR2-ζ RMTC as opposed to the MSCV control cells or MBP-DR2 
RTMC. 
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Figure 4-17. Cytolysis of primary CD8+ DTG target cells by RMTC measured by 
stimulation of residual MBP-DR2-specific T-cells. T lymphocytes from DTG mice 
TCR/DR2 were cocultured with therapeutic cells or MSCV retroviral control in three 
different ratios in the absence or presence of DR2+ antigen-presenting cell line (EL4-
MBP-DR2) for five days. At the end of the fifth day, the residual cells were stained with 
hVβ2 and mCD4 antibodies and quantitative FACS analysis was performed. We found a 
considerably lower number of residual CD8+ peptide-specific cells when these were 
cocultured with MBP-DR2-ζ RMTC as opposed to the MSCV control cells or MBP-DR2 
RTMC. 
 
 
 102 
other RTMC (MBP-DR2 and MSCV control) showed this ability. Moreover, both CD4 
and CD8 antigen-specific cell lines survived and expanded after six hour-coculture with 
tailless RMTC or MSCV control cells. Prior data show that RMTC are only able to kill 
primary CD8+ antigen-specific T-cells and not stimulated CTL and that activated CD8+ 
antigen-specific T-cells are resistant to fratricidal lysis (56). Our experience with the 
antigen-specific T-cell lines from humanized transgenic mice yielded the same results: 
CD4+ antigen-specific T-cells can be killed by the tail-bearing RMTC, whereas CD8+ 
antigen-specific T-cells survived after coculture with MBP-DR2-ζ RMTC (Figures 4-18 
and 4-19). 
 
4.4 Conclusions 
We developed receptor-modified T-cells that can specifically recognize and target 
pathologic, antigen-specific T lymphocytes by transducing chimeric receptors into 4G4 T 
cell hybridoma or primary murine T-cells. The MBP-DR2-ζ CR heterodimer bears an 
antigen-MHC extracellular domain linked to the functional ζ signaling moiety from the 
TCR. The MBP-DR2 CR lacked the cytoplasmic signaling domain. Both constructs were 
subcloned in MSCV retroviral vector with an IRES site and GFP gene. Their surface 
expression was proportional to level of expression of the GPF protein. Transduction of 
4G4 T cell hybridoma with the ζ-bearing and ζ-deficient retrovirus showed similar 
surface levels of expression whereas transduction of activated, primary T-cells showed a 
discrepancy between the two CRs, with a 30% increase in surface expression of the 
tailless CR. Upon encounter of cognate TCR on the surface of Ob target hybridoma 
(specific for hMBP84-102 restricted by HLA-DR2), therapeutic RMTC recognized the  
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Figure 4-18. Cytolysis of CD4+ hMBP-specific cell lines by RMTC. Antigen-specific 
CD4+ cell lines were obtained by repeated stimulations of T lymphocytes from TCR/DR2 
DTG mice with EL4-MBP-DR2 cells. Each line was then cocultured with RTMC for six 
hours and the residual cells were then stained for hVβ2 and mCD4 antibodies. MBP-
DR2-ζ RMTC were able to efficiently kill the CD4+ peptide-specific cell line. 
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Figure 4-19. Cytolysis of CD8+ hMBP-specific cell lines by RMTC. Antigen-specific 
CD8+ cell lines were obtained by repeated stimulations of T lymphocytes from DTG 
mice TCR/DR2 with EL4-MBP-DR2 cells. Each line was then cocultured with RTMC 
for six hours and the residual cells were then stained for hVβ2 and mCD8 antibodies.  
Unlike CD4+ peptide-specific cell lines, the CD8+ T-cells could not be killed by the 
MBP-DR2-ζ RMTC. 
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target cells, responded by proliferation, secretion of IL-2 and IFN-γ, and were able to 
specifically kill target cells. The in vitro cytolytic ability of CTL RMTC was significant: 
effector cells killed over 70% of target cells when cocultured in a 1:1 effector to target 
ratio and even up to 90% when five times more effectors were added to the target cells. 
Cytolysis was only detected in RMTC transduced with the ζ-bearing CRs, but not MSCV 
control or the ζ-deficient RMTC.  
Several attempts to direct RMTC against naïve, antigen-specific T-cells from 
lymph nodes of TCR/DR2 humanized transgenic mice failed repeatedly in a six hour-
killing assay or overnight killing. Analysis of these double transgenic mice revealed that 
only 0.5% for their T-cells were peptide-specific cells in an ELISPOT analysis (85). 
Therefore, the reduced ability of MBP-DR2-ζ RMTC to specifically kill target cells and 
the lack of difference between the activity of ζ-bearing and ζ-deficient RMTC and MSCV 
control was rather due to the very low number of antigen-specific cells that could not be 
detected and isolated from the non-specific. The latter cells would not be subjected to 
RMTC lysis, but would interfere in the assay, making identification of specific cytolysis 
of hMBP-specific T-cell impossible to detect. We adopted an alternate way to stimulate 
antigen-specific cells using a DR2+ antigen-specific cell line (EL4-MBP-DR2) to 
selectively expand only residual antigen-specific cells. Five days later, we noticed a 
decreased number of both CD4+ and CD8+ hMBP-specific T-cells when cocultured with 
MBP-DR2-ζ RMTC in the presence of DR2+ cell line, but an expansion of these cells 
when cocultured with MBP-DR2 or MSCV control RMTC. These data show that the ζ-
CR-transduced RMTC can also kill naïve antigen-specific T-cells from TCR/DR2 double 
transgenic mice in the presence of antigen, whereas removal of the signaling domain 
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from the CR impeded this ability. Surprisingly, although the humanized transgenic mice 
have T-cells specific for hMBP presented in the context of DR2, an MHC class II 
molecule, upon antigenic stimulation, both CD4+ and CD8+ T-cells from TCR/DR2 mice 
responded by proliferation. Although fairly rare, this is not an isolate finding and 
accounts for the coreceptor independence of CD8+ TCR/DR2 T-cells. 
 The ability of MBP-DR2-ζ RMTC to kill naïve, antigen-specific T-cells from 
TCr/DR2 mice did not apply in the case of peptide-specific cell lines. Stimulated T 
lymphocytes behave differently from naïve T lymphocytes. We built a CD4 and a CD8-
specific cell line by several rounds of antigenic stimulation using DR2+ antigen-
presenting cells. Just like naïve CD4 T-cells, peptide-specific CD4+ cell lines were killed 
upon in vitro coculture with the tail-bearing RMTC, but not MSCV control or ζ-deficient 
therapeutic cells. CD8+ hMBP-specific cell line proved resistant to lysis. This fact was 
demonstrated in the early 1990s and we have also proven that CD8 T-cells acquire 
resistance to lysis in between day three and seven post stimulation (56). EAE is 
classically considered a CD4 disease and therefore, the ability of our MBP-DR2-ζ RMTC 
to specifically kill both naïve and activated CD4+ hMBP-specific cell lines are grounds to 
hypothesize that they might also work in the in vivo mouse model. 
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Chapter 5. In vivo activity of RMTC in humanized mice 
 
5.1 Introduction 
 
5.1.1 Humanized transgenic mice as MS models 
Similar to other autoimmune diseases (rheumatoid arthritis, celiac disease, 
insulin-dependent diabetes), MS is associated with certain MHC class II genes. The 
disease is triggered by association of autoantigenic peptides with certain MHC class II; 
MHC-peptide is recognized by CD4+ T-cells that, upon activation, mediate inflammation 
and destruction of the myelin sheath, ultimately leading to impaired saltatory conduction 
(93).  
In the previous chapter, we described the development of RMTC as therapeutic T 
lymphocytes bearing humanized chimeric receptors, which can be redirected against 
antigen-specific T-cells. Upon encounter of target, hMBP-specific T lymphocytes, 
therapeutic cells will engage the target cells’ TCR through their surrogate chimeric 
receptor, leading to various effector functions, such as proliferation, cytokine secretion, 
and specific cytolysis of peptide-specific cells. 
 Once we have shown that RMTC can recognize cognate TCR and exhibit effector 
functions in response to this recognition, the next step was to test whether this interaction 
would lead to the same effects in vivo. 
In an effort to better understand autoimmune diseases and MS in particular, mice 
that express disease-relevant MHC II molecules have been developed. These mice were 
then crossed with mice transgenic for other genes encoding TCRs, human CD4, and 
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candidate autoantigens. Since they bear human genes, these mice present similar disease 
features either spontaneously or after immunization with peptides. Although they are not 
a perfect representation of the human immunopathology, these animals are, nevertheless, 
the closest mouse model to study MS-causing mechanisms and symptoms (87). 
 
5.1.2 Humanized HLA-DR2, TCR, and CD4 mice 
After analyzing autoantigens and MHC molecules associated with MS, studies 
have shown that one of the immunodominant MBP peptide epitope in DR2+ patients was 
84-102. This epitope was identical in humans and mice (94). 
Serologic typing of patients serum has identified the common MHC class II 
molecule as HLA-DRB1*1501 and DRA*0101 that recognized the MBP peptide (86). 
Based on these data, Fugger and collaborators engineered three humanized transgenic 
mice. A first mouse bore the human DR2 gene (HLA-DRB1*1501 and DRA*0101) 
expressed under the control of its native promoters. A second mouse bore a TCR derived 
from a patient with MS, denoted Ob (Ob.1A12). Because human TCR is difficult to 
express in mouse cells, the TCR construct comprised human variable domains and mouse 
constant and regulatory domain. This set-up ensures that the MBP peptide will be able to 
be recognized and bound by the human MHC class II and, since the constant and 
signaling domains of the TCR are murine, they could interact with the mouse signaling 
machinery. These two strains of transgenic mice were crossbred and then also crossed 
with another transgenic mouse carrying the human CD4 coreceptor. Caveats of this 
double and triple transgenic mouse model are that only 10-30% of B-cells were DR2+ and 
only 80% of T-cells were Vβ2+ (87). T-cells from these mice showed proliferation and 
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IL-2 secretion in response to hMBP84-102 stimulation. Upon immunization with peptide, 
the mice developed relapsing-remitting or primary progressive EAE similar to MS 
patients and with similar histopathologic aspect. Single transgenic TCR or HLA-DR2 
mice did not develop signs and symptoms of EAE following MBP immunization. 
Breeding of the double transgenic TCR/DR2 mice with Rag2-/- mice leads to 
development of spontaneous EAE due to the complete absence of T and B lymphocytes 
(including regulatory T-cells) in these knockout mice and repopulation of their immune 
system with hMBP-specific cells.  
 
5.2 Materials and methods 
 
5.2.1 In vivo cytolysis of CD4+ and CD8+ hMBP-specific cell lines by RMTC 
 Recombination activating gene 2 knockout mice (Rag2-/-) were kept in 
Helicobacter pylori-free facility of the Animal Research Center at St. Jude Children's 
Research Hospital. These mice were coinjected with 5x106 mixed CD4+ and CD8+ triple 
transgenic cells from T-cell lines and 20x106 receptor-modified CTLs. CD4+ and CD8+ 
peptide-specific cell lines were obtained by three consecutive stimulations of T-cells 
from TCR/DR2 transgenic mice with irradiated antigen-presenting cell line (EL4-MBP-
DR2) every ten days, according to the protocol described in chapter 4.2.5.2. After three 
days, recipient mice were sacrificed and spleens were processed in a single cell 
suspension, followed by double staining of splenocytes human Vβ2/mouse CD4 and CD8 
antibodies and flow cytometry analysis.   
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5.2.2 In vivo cytolysis of naïve antigen-specific T-cells by RMTC 
Irradiated (450 rad) transgenic humanized DR2 mice (strain Fug5) received 
10x106 freshly isolated T-cells from TCR/DR2 transgenic mice and 30x106 therapeutic 
RMTC by retroorbital injection. Two irradiated recipient Fug5 mice were used for each 
group (MSCV control, MBP-DR2-ζ, and MBP-DR2 RMTC).The mice were sacrificed 
after nine days or the indicated time. Lymph nodes (LN) were collected and processed to 
obtain a single cell suspension. 105 cells/well were stimulated for three days in the 
presence or absence of antigen (2x105 EL4-MBP-DR2 cells or EL4 cells, respectively, 
irradiated at 20,000 rad). 72-hours later, the cells were pulsed with 1µCi [3H] thymidine 
and harvested on filtermats after 16 hours. Proliferation was measured by liquid 
scintillation counting of incorporated [3H]thymidine. The samples were analyzed in 
duplicates.  
 
5.2.3 Prevention of EAE induced by naïve CD4+ T-cells from TCR/DR2/hCD4 using 
RMTC 
 Lymph nodes and spleen from ten TCR/DR2/hCD4 transgenic mice were 
processed in a single cell suspension and stained for PE anti-mouse CD4 microbeads. 
Cells were then separated by magnetic cell sorting (Miltenyi Biotec Inc., Auburn CA). 
13x106 pure CD4+ T-cells were then transferred into 8 irradiated Fug5 recipients along 
with 35x106 RMTC. Two days later, the mice were immunized with 300 µg hMBP84-
102 and 400 ng PTx on day 0 and 2. The animals were scored daily for signs of EAE 
disease and euthanized at score 4 to 5 (complete paralysis or moribund). 
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5.2.4 Prevention of hMBP84-102-induced EAE disease in TCR/DR2 double transgenic 
mice using therapeutic cells 
TCR/DR2 transgenic mice were immunized with 300 µg hMBP84-102 and at the 
same time, received the indicated numbers of MBP-DR2-ζ, MBP-DR2 or MSCV control 
RMTC. 400 ng PTx was injected retroorbitally at the time of peptide injection and on day 
2. Mice were followed and scored daily for signs of EAE. 
 
5.3 Results 
 
5.3.1 In vivo cytolysis of CD4+ and CD8+ hMBP-specific cell lines by RMTC 
This experiment was designed to investigate the in vivo efficacy of therapeutic 
RMTC in vivo when coinjected with hMBP-specific cell lines into Rag-/- mice for three 
days. Upon interaction with the antigen-specific cell lines, RMTC transduced with 
chimeric receptor MBP-DR2-ζ and the MBP-DR2 recognized the specific target cells and 
exhibited their effector function, namely cytolysis of CD4+ antigen-specific cells. As 
expected from previous data, CD8+ MBP-specific cell line did not undergo cytolysis. 
Surprisingly, even though MBP-DR2-transduced RMTC failed to show any effector 
function in vitro due to the absence of the ζ cytoplasmic signaling tail, in vivo co- 
adoptive transfer of these cells along with MBP-specific cell lines showed almost 
the same efficacy of killing as the MBP-DR2-ζ RMTC (Figure 5-1). 
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Figure 5-1. In vivo killing of CD4+ hMBP-specific cell line by RMTC. CD4+ and 
CD8+ hMBP-specific cell lines and RMTC were coinjected into Rag2-/- recipients. Three 
days later, mice were sacrificed, splenocytes were stained with mouse anti-human 
Vβ2/rat anti-mouse CD4 or CD8 antibodies, and analyzed by FACS. The plot represents 
the number of cells found in spleens after three days treatment with RMTC. 
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5.3.2 In vivo cytolysis of naïve antigen-specific T-cells by RMTC 
 The previous experiment confirmed that CD4+ antigen-specific cell lines could be 
killed by MBP-DR2-ζ RMTC, but these effector cells cannot kill CD8+ hMBP-specific  
cell lines. The next step was to find out if whether this also applies to naïve peptide-
specific T-cells. We coinjected freshly isolated cells from TCR/DR2 transgenic mice 
along with RMTC into irradiated recipients, sacrificed them after nine days, and looked 
for residual peptide-specific cells after stimulation with antigen (irradiated EL4-MBP-
DR2 cells) or in the absence of antigenic stimulation (irradiated EL4 cells). T-cells from 
lymph nodes of MBP-DR2-ζ RMTC-injected recipients showed little proliferation in 
response to antigenic stimulation and decreased number of residual cells compared to the 
mice that received MBP-DR2 RTMC or MSCV control virus. These results demonstrate 
that the signaling-competent therapeutic cells effectively eliminate hMBP-specific T-cells 
in vivo and further demonstrate that signaling through the ζ cytoplasmic tail is essential 
for this activity (Figure 5-2). 
 
5.3.3 Prevention of EAE induced by naïve CD4+ T-cells from TCR/DR2/hCD4 using 
RMTC 
To find out whether EAE induced by adoptive transfer of CD4+ T-cells from 
transgenic mice (as described in 5.2.3) could be prevented by MBP-DR2-ζ RMTC, we 
followed all three groups of mice daily for signs of disease. The first signs of EAE in the 
group that received MSCV CTLs became visible after only 7 days and followed a 
progressive course with very little remission. The mice that received ζ-CR RMTC did not 
show any signs of disease. This pilot experiment, which requires repetition, shows that 
 114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2. Peptide stimulation of T-cells from mice that received RMTC and naïve 
antigen-specific target cells. Cells from mice that received TCR/DR2 cells and RMTC 
for nine days were stimulated in the presence/absence of antigen for 72-hours and 
[3H]thymidine was added. 16-hours later, the cells were harvested onto filtermats and 
proliferation was measured by liquid scintillation counting. hMBP-specific cells from 
mice that received retroviral vector control and the MBP-DR2 RMTC proliferated in 
response to antigen as opposed to the ones that received the MBP-DR2-ζ RMTC. 
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upon depletion of CD8+ T-cells, CD4+ lymphocytes cause and therapeutic RMTC can 
prevent it. We can conclude that in this particular system EAE is still a CD4-mediated 
disease and that the MBP-DR2-ζ RMTC still have therapeutic potential (Figure 5-3 and 
Table 5-1).  
 
5.3.4 Prevention of hMBP84-102-induced EAE disease in TCR/DR2 double transgenic 
mice using therapeutic cells 
 This experiment is the first attempt to prevent EAE in the humanized mouse 
model using humanized chimeric receptor-transduced RMTC. We injected two groups of 
mice with MSCV control and MBP-DR2-ζ RTMC and followed them daily for signs of 
EAE. We first noticed an earlier disease onset in the MSCV control group and also a 
more aggressive disease course with only mild remission. Contrary to this group, mice 
that received MBP-DR2-ζ therapeutic RTMC exhibited a significant delay in the onset of 
disease as well as a shorter course and complete remission. These in vivo results are 
confirming our in vitro data and prove the restorative potential of ζ-endowed RMTC 
(Figure 5-4 and Table 5-2). Even though we did not have any tailless RMTC to inject in 
the mice (due to a low number of ζ-deficient RMTC that we obtained by in vitro 
stimulation), this was encouraging data and a further proof that administration of ζ-CR-
transduced RMTC might be a valid therapeutic option for EAE treatment in this 
humanized mouse system. Therefore, we repeated this experiment using 30x106 RMTC 
bearing both chimeric receptors and immunizing the mice two days later. Surprisingly, 
not only did the MBP-DR2-ζ RMTC proved beneficial, but so did the tailless therapeutic 
cells, although not in the same extend as the former ones. This might actually raise 
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Figure 5-3. Prevention of CD4+-adoptive transfer EAE with RMTC. Irradiated Fug5 
recipients received concomitantly sorted CD4+ target cells from TCR/DR2/hCD4 
transgenic mice and therapeutic RMTC followed by immunization with hMBP84-102 
peptide and PTx. Recipients of MSCV control cells showed early disease onset and 
severe course with little remission as opposed to the ones that received therapeutic MBP-
DR2-ζ RMTC that were resistant to EAE induction. 
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Table 5-1. Clinical manifestations in CD4+ adoptive transfer EAE treated with 
RMTC. 
 
 
 
Therapeutic cells Disease frequency Mean onset Mean maximal 
  (diseased/total) day x±s.d. (range) score x±s.d.  
  MSCV 4/4 9.5±7 3±2.3 
  MBP-DR2-ζ 0/0  0±0  0±0 
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Figure 5-4. Prevention of EAE with ζ-bearing RMTC. TCR/DR2 mice received MBP-
DR2-ζ RMTC or MSCV control cells and were immunized with peptide and PTx. 
Control group showed early onset and severe disease course, whereas treated group had a 
milder form of disease followed by complete remission. 
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Table 5-2. Clinical manifestations in direct induction of EAE with hMBP and 
treatment with MSCV vector control or ζ-bearing RMTC. 
 
 
 
Therapeutic cells Disease frequency Mean onset Mean maximal 
  (diseased/total) day x±s.d. (range) score x±s.d.  
  MSCV 4/4 8.75±3.5 3.5±1.7 
  MBP-DR2-ζ 4/5  11.8±6.6 1.6±1.1 
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question about the absolute requirement for the cytoplasmic signaling tail in the chimeric 
receptor for the in vivo treatment of EAE (Figure 5-5 and Table 5-3). 
 
5.4 Conclusions 
 The results obtained from in vitro testing of RMTC encouraged us to move 
forward to the in vivo system. We coinjected therapeutic RMTC along with either 
peptide-specific cell lines or naïve antigen-specific cells obtained from the transgenic 
mice into recipient Rag-/- or irradiated DR2 (Fug5) mice. We sacrificed the mice at 
various intervals, starting from day 3 to 9, and estimated the number of residual CD4 and 
CD8 antigen-specific T-cells. According to our in vitro data, therapeutic RMTC bearing 
the ζ-signaling tail should be able to specifically recognize and kill naive antigen-specific 
T-cells. When we sacrificed recipient mice nine days after coinjection of MBP-DR2-ζ 
and naïve target cells, we found a decreased number of hVβ2+CD4+/CD8+ T-cells. Since 
we have already established that very few of the target cells provided by TCR/DR2 mice 
are antigen-specific, we stimulated cells from lymph nodes and spleen of recipient mice 
with antigen as previously described. T-cells from irradiated recipients that received 
MBP-DR2 and MSCV-control RMTC along with naïve antigen-specific cells showed 
good proliferation upon peptide stimulation unlike mice that received MBP-DR2-ζ 
RMTC. These data resemble the ones we obtained from in vitro experiments and prove 
that recognition through surrogate chimeric receptor also takes place in the mouse 
system. Surprisingly, when Rag-/- recipients received both therapeutic cells and hMBP-
specific cell lines, both ζ-bearing and ζ-deficient RMTC were effective in eliminating the 
CD4+ peptide-specific cell line. We did not pursue this observation, but the fact that 
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Figure 5-5. Prevention of EAE with ζ-bearing or tailless RMTC. Three groups of 
TCR/DR2 transgenicmice received MBP-DR2-ζ, MBP-DR2, and MSCV control RTMC 
and 48 hours later peptide and PTx. Control group showed early onset and severe disease 
course, whereas ζ-competent therapeutic cells showed a later onset and milder disease 
followed by complete remission. ζ-deficient therapeutic cells showed an intermediate 
effect, but still managed to induce remission although not in the same extent as MBP-
DR2-ζ RMTC. 
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Table 5-3. Clinical manifestations in direct induction of EAE with hMBP and 
treatment with MSCV control, ζ-bearing, or tailless RMTC. 
 
 
 
Therapeutic cells Disease frequency Mean onset Mean maximal 
  (diseased/total) day x±s.d. (range) score x±s.d.  
  MSCV 4/4 8.5±1 5±0 
  MBP-DR2-ζ 3/3  14±0  1±0  
  MBP-DR2 4/4  13±0 3±1.4 
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stimulated cells are more prone to Fas-induced apoptosis might provide an explanation 
for this finding. Just like the in vitro data, RMTC with or without signaling tail were 
unable to kill the CD8+ peptide-specific cell line. 
We proceeded to test the ability of chimeric receptor-modified T-cells to prevent 
EAE disease either by direct injection of these cells into recipient, TCR/DR2 mice, 
followed by immunization with hMBP84-102, or by adoptive transfer of therapeutic cells 
along with target cells into DR2+ mice. Adoptive transfer of both RMTC and freshly 
isolated, naïve cells from TCR/DR2 mice resulted in worse disease scores and earlier 
onset of paresis and paralysis in mice that received MSCV or tailless RMTC compared to 
those that received MBP-DR2-ζ T-cells. This does not necessarily mean that therapeutic, 
ζ-bearing RMTC are less potent than they have shown to be in vitro, but rather 
insufficient number of cells compared to the number of antigen-specific, naïve target 
cells. Our next step was to sort CD4 and CD8 T-cells from TCR/DR2 transgenic mice 
and only adoptively transfer CD4+ T-cells and RMTC into irradiated DR2+ humanized 
transgenic mice, followed by immunization with peptide. There was no development of 
EAE in mice that received MBP-DR2-ζ RMTC, as opposed to MSCV-control cells. 
Although we did not have MBP-DR2 RMTC available for this particular experiment, the 
fact that ζ-CR-transduced effector cells could efficiently eradicate CD4+ target cells is 
proof that these therapeutic cells are potent not only in vitro but also in vivo in EAE 
prevention. Finally, upon direct transfer of therapeutic cells into TCR/DR2 mice and 
induction of EAE disease by peptide immunization, mice that received ζ-bearing RMTC 
showed later onset of disease with milder course. Quite unexpectedly and unlike our in 
vitro data, ζ-deficient RMTC recipients have also shown a milder EAE course and later 
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onset compared to MSCV control mice, though their potency was lower than the one 
exhibited by the ζ-bearing therapeutic cells. 
All these data lead us to believe that surrogate ζ-chimeric receptor-transduced 
RMTC as just as effective in killing antigen-specific T-cells from TCR/DR2 mice in 
vivo as they were in vitro, thus preventing EAE disease. A question that rises naturally is 
whether these therapeutic cells would also work after the first signs of EAE disease in 
forestalling the fatal outcome and improving the clinical signs and symptoms, and this 
may be a topic for future studies. 
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Chapter 6. Discussion 
 
 Multiple sclerosis is the most common autoimmune disease involving the white 
matter of the CNS. It is reported to affect 300,000 Americans with 200 people diagnosed 
weekly and 2.5 million people worldwide (2). The neurologic signs and symptoms of MS 
are varied and can also present in other diseases. Double vision, paralysis, tremor, 
numbness, and gait difficulties are caused by demyelination resulting in impaired nerve 
conduction; axons and cell bodies are spared early in the disease. The initial disease 
target is the white matter of the brain and spinal cord, but after a while the gray matter 
also becomes involved due to secondary degeneration resulting from the loss of the white 
matter. Axons will eventually be destroyed and replaced by gliosis that gives the sclerotic 
aspect on MRI.  
There are currently several therapies approved for MS. Regardless of the 
approach, treatment should target both the symptoms and the pathologic cascade. 
 Gene therapy is the newest approach in the treatment of MS. It has emerged as a 
direct result of increased knowledge concerning pathologic mechanisms in autoimmune 
diseases and aims to more specifically target pathologic T-cells than current therapies. 
Anti-inflammatory cytokine genes can be delivered into the CNS by viral vectors. More 
recently, our laboratory has developed receptor-modified T-cells bearing chimeric 
receptors that specifically target autoreactive T-cells. A similar approach has already 
been used in infectious diseases and cancer.  
 Chimeric receptors are hybrid molecules that encompass a recognition domain – 
the variable region involved in antigen recognition from MHC or Ig – and a signaling 
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domain – the intracytoplasmic signaling moieties of the TCR. This new therapeutic 
approach emerged in the 1980s-1990s when it was found that T-cells endowed with 
antibody-like abilities and no MHC restriction can be redirected against infected and 
neoplastic cells. The necessity of having a signaling domain resides in the fact that 
recognition of antigen by the variable region of the chimeric receptor is not sufficient to 
activate T-cells. Similar to the cascade of events triggered in a regular T lymphocyte, T-
cells bearing chimeric receptors undergo phosphorylation of ITAMs on the receptor’s 
signaling moiety and turn on the transcription of nuclear factors responsible for activation 
of these cells, thus inducing effector function. Engagement of the TCR constitutes the 
first signal necessary for activation of T lymphocytes but for a full activation a second 
signal is mandatory. This can be through either of several molecules including the CD28 
molecule that stimulates the expansion of CD4+ cells and CD137 (or 4-1BB) that 
prevents activation-induced cell death of activated T-cells and stimulates the expansion 
of CD8+ cells. 
The choice of the cytoplasmic signaling domain has long been a critical topic in 
the design of chimeric receptors. Increasing the number of ITAMs did not necessarily 
enhance signaling of the CR (95). In an attempt to test the effect of different signaling 
domains on the potency of signal transduction, several intracytoplasmic domains have 
been used in a CR engineered to bear the recognition domain of MHC class I (Kb) 
molecule. The combinations of CD28-zeta, zeta-lck, CD4-zeta, and CD28-zeta-lck 
signaling domains increased receptor function measured by IL-2 secretion after 
stimulation with the anti-Kb specific antibody.  
Although CRs bearing the intracytoplasmic CD28 moiety showed very high 
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efficacy of signal transduction, their surface expression level decreased compared to CRs 
that only had ζ signaling tail. We examined the sequence of CD28 and found a previously 
unrecognized dileucine motif. Dileucine motifs are normally present very close to the 
membrane in the cytoplasmic tail of transmembrane proteins and are recognized by coat 
proteins involved in lysosomal targeting. Proteins bearing this amino acid sequence are 
internalized and transported to the endosome and eventually to the lysosome, decreasing 
their surface expression. We hypothesized that a leucine to glycine (L G) mutation in 
the dileucine motif could potentially not only improve the surface expression of the 
construct, but also the duration and intensity of the signal transduced. Indeed, when 
stimulated with the CR-specific antibody, anti-Kb, there was an enhanced production of 
IL-2 from CD8+ T-cells transduced with the Kb-CD28 (L G)-ζ compared with cells 
transduced with Kb-ζ CR. In addition, there was an increased proliferative response to the 
antibody and increased cytotoxic activity against Kb-restricted target cells. These data 
show that a mutation in the dileucine motif of the CD28 intracytoplasmic moiety 
increases the intensity of the signal transduction events.   
The primary rationale for transducing chimeric receptors into T lymphocytes in 
MS is the production of therapeutic, receptor-modified T-cells able to tolerize or even kill 
autoantigen-specific target cells. Autoreactive T-cells are normally stimulated upon 
encounter of an antigenic peptide bound to MHC on the surface of APCs. Since CRs can 
bear both an MHC class II recognition domain (extracellular and transmembrane parts) 
that has the peptide linked to the surface and the intracytoplasmic signal transduction 
domain, upon transduction into T lymphocytes the cells will acquire both APC and TCR 
abilities (peptide presentation and T cell effector function). The encounter between 
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effector and target cells bearing the chimeric receptor and a normal TCR respectively, 
leads to stimulation of both cell populations. Stimulation of RMTC is a critical feature of 
this system because it leads to the fulfillment of their effector functions: proliferation, 
cytokine secretion, and cytolysis of target. In a mouse system, therapeutic T-cells 
transgenic for heterodimeric CRs bearing the recognition domain of MHC class II IAsβ 
chain linked to MBP89-101 and a ζ signaling tail paired with IAsα chain-ζ, were able to 
express the CR on the surface and were stimulated by MBP89-101-specific 6F11 target 
hybridoma. They secreted cytokines, proliferated, and managed to kill autoreactive CD4+ 
T-cells and were not killed by them. These data show that the two cell types interact via 
CR-cognate TCR recognition and effector function occurs following this recognition.  
The key goal in using RMTC is the prevention and/or treatment of EAE disease. 
SJL/J mice immunized with MBP89-101 peptide were treated with therapeutic cells or 
PBS control at the time of disease induction. The treated animals were completely 
protected from EAE and suppression of disease was antigen-specific. Although 
protection was more efficient when the animals received therapeutic cells concomitantly 
with antigenic peptide, administration of cells even after the onset of disease symptoms 
was still effective, albeit slightly less so and with a delayed kinetic compared with 
treatment at the time of immunization. The explanation for this may reside in the status of 
the autoreactive T-cells. In the first scenario, the cells did not experience a previous 
encounter with antigen and are, therefore, naïve, whereas in the second situation, upon 
immunization with peptide, target antigen-specific T-cells had already been stimulated, 
expanded, and mediated some damage to the CNS.  
The mechanism by which RTMCs exercise their therapeutic function is inhibition 
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of antigen-specific T cell response of target cells which may occur through the killing of 
the target cells. In addition to this, pathologic cells are skewed from Th1 to Th2 type and 
secrete anti-inflammatory cytokines, such as IL-4, instead of IFN-γ. 
In the work described here, we proposed extending our studies in murine EAE by 
developing a new model for the therapy of MS using humanized chimeric receptors. We 
designed two constructs based on the same principle that has already been described for 
CRs. The first construct, MBP-DR2-ζ, had a recognition domain composed of an 
immunodominant MBP epitope (84-102) linked to the β chain of a HLA class II molecule 
(DR2) and a signaling domain composed of the ζ cytoplasmic signaling tail.The α chain 
of DR2 was also linked to ζ. The DR2 HLA molecule is highly associated with MS 
disease, and T-cells specific for the MBP84-102 epitope can be detected in DR2 patients 
with MS.  We then engineered a second CR, MBP-DR2 that lacked the signaling tails to 
identify the role of signal transduction for the in vitro and in vivo efficacy of this 
particular CR. The constructs were each tricistronic, with the β and α chains separated by 
a 17-mer 2A sequence from T. asigna and an IRES linked to GFP. Both constructs were 
subcloned into MSCV retroviral vector. CRs were transduced in either 4G4 TCR- 
hybridoma or primary murine T lymphocytes from C57Bl/6 mice, sorted for GFP 
expression and expanded in complete Bruff medium and IL-2. 
The tail-bearing and tailless CRs showed good surface expression on flow 
cytometry in both 4G4 and primary T-cells when stained with anti-CR specific antibody 
mouse anti-human DR2. Transduced hybridoma showed similar levels of expression of 
CR; transduced T-cells showed better expression of the tailless CR compared to the ζ tail-
bearing one (71.7% versus 40.4%). 
 130 
 We first wanted to see if receptor-modified T-cells bearing TCR-ζ, tailless CRs, 
or MSCV retroviral vector control could be stimulated by plate-bound DR2-specific 
antibody. Only MBP-DR2-ζ responded to stimulation by secreting IL-2. 
We next looked for the ability of CR-transduced T-cells to recognize the cognate 
TCR on the surface of target cells. The latter were either Ob1A12 hybridoma specific for 
hMBP84-102/DR2 T-cells or T cell lines from the double or triple transgenic mice, 
TCR/DR2 and TCR/DR2/hCD4, respectively, with similar specificity. These humanized 
mice have develop a disease that strongly resembles human MS model; they carry one of 
the most frequent immunodominant epitope of myelin basic protein, 84-102, presented by 
one of the most frequently used class II MHC in MS patients, DRB1*1501. Even though 
very few of the T-cells in the transgenic mice were MBP-specific in Tg mice bred on a 
Rag+/+ background, on a Rag-/- background all of the T-cells will express exclusively the 
Tg receptor and these mice develop spontaneous EAE. We further demonstrated that both 
CD4 cells and CD8 cells from the double Tg mice responded to MBP peptide restricted 
to the DR2 (DRB1*1501) HLA molecule.  Thus the T cell response in these mice is not 
coreceptor dependent.  As controls we used other targets, specifically 6F11 hybridoma 
reactive against MBP89-101/IAs and T-cells from non-Tg mice.  
Upon recognition of cognate TCR on the surface of Ob1A12 specific hybridoma 
but not 6F11 controls, RMTC bearing the ζ signaling tail were stimulated and secreted 
IL-2 and IFN-γ. Also, due to the interaction between the two cells, RMTC and target 
Ob1A12 cells, RMTC proliferated and killed the target cells. The cytolytic effect was 
specific and very effective as even at a 1:1 ratio effector to target ratio, the RMTC 
managed to eliminate over 70% of the targets. It is noteworthy that only the cells bearing 
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the cytoplasmic signaling tail were capable of both proliferation and killing upon 
recognition of cognate TCRs.         
 Our attempt to demonstrate similar results in cytolysis assays using primary 
murine antigen-specific cells from lymph nodes or spleens of DTG (TCR/DR2) mice did 
not yield the same results. In vitro overnight killing assays in which RMTC targeted T-
cells from transgenic mice showed very little difference between control and 
experimental cultures. This seemed be due to the fact that although 80% of T-cells in the 
humanized transgenic mice were hVβ2+, only ~ 0.5% of them are hMBP84-102-specific 
in ELISPOT assays. Therefore a preponderance of non-antigen-specific cells that cannot 
be recognized and killed by RMTC were present therefore preventing detection of any 
target cell lysis.  
We approached this problem in two ways.  First, we developed a functional assay 
to overcome it in which we stimulated T-cells with antigen in vitro for five days. The 
MBP-specific cells survive, get activated, and proliferate in response to peptide, whereas 
the non-specific cells die. After 5 days we could demonstrate that virtually all surviving 
T-cells are antigen specific. We treated cultures at the time of antigen-stimulation either 
with control MSCV-vector transduced RMTC, MBP-DR2 RMTC or MBP-DR2-ζ 
RMTC.  After 5 days we used quantitative flow cytometry to determine the number of 
surviving T-cells.  This demonstrated that the MBP-specific cells were killed by ζ-
bearing RMTC, whereas the target cells cocultured with MSCV control or tailless RMTC 
proliferated due to peptide stimulation. Surprisingly, these results were true not only for 
CD4+ antigen-specific cells, but also for the CD8+ MBP-specific cells.     
As a second approach, we established T cell lines using T-cells from DTG 
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(TCR/DR2) or TTG (TCR/DR2/hCD4) mice stimulated repeatedly with exogenous 
antigen (irradiated EL4-MBP-DR2 cells) and used them to test the cytolytic ability of 
RMTC. Results showed that, unlike the previous experiment where therapeutic cells 
bearing the signaling tail were capable of killing naïve, CD4 and CD8 antigen-specific T-
cells, the RMTC could not achieve the same outcome with CD8+ hMBP-specific cell line. 
CD8+ T-cells develop resistance to lysis between days 3 and 7 after activation and this 
might explain the lack of potency of the RMTC in killing the CD8+ cell line (57).  It may 
also impair the therapeutic usefulness of RTMCs in EAE models, such as potentially the 
TCR/DR2 model of ours, where class II restricted CD8 T-cells may have a pathologic 
role. 
We went on to test our RMTC in vivo.  These studies highlighted the in vitro 
results and provided evidence for the therapeutic applicability of humanized RMTC. 
Adoptive transfer of freshly isolated lymphocytes from humanized transgenic mice 
TCR/DR2 along with therapeutic cells into irradiated humanized DR2 recipients showed 
decreased proliferation upon antigenic stimulation in mice treated with the ζ- bearing 
RMTC as opposed to a vigorous proliferative response generated in mice that received 
MSCV control or tailless RMTC.  
Adoptive transfer of antigen-specific cell lines and therapeutic cells into Rag-/- 
mice followed by treatment with RMTC yielded somewhat different results. As we saw 
in vitro, the number of CD8+ peptide-specific cell line cells was not diminished by either 
ζ- or tailless RMTC when compared with the control treatment. Therefore these cells 
seemed to be resistant to lysis in vivo, much as they were in vitro.  Results with the CD4 
cell line were more surprising.  Not unexpectedly, the number of residual CD4 peptide-
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specific cells was decreased in mice injected with MBP-DR2-ζ RMTC. However, mice 
injected with MBP-DR2 RMTC showed a similar and nearly complete loss of these cells. 
This in vivo effect of the tailless CR-transduced cells could not be predicted based on any 
of the in vitro experiments. One potential explanation for the difference is that 
stimulation by the MBP-DR2 RMTC in vivo induces the MBP-reactive cell line but not 
naive T-cells to undergo activation induced cell death.  However, at the current time 
experimental evidence to support this does not exist. 
The ultimate goal of this project is to prevent or treat EAE in a humanized mouse 
model. We adopted two approaches. The first one was to adoptively transfer cells from 
triple transgenic TCR/DR2/hCD4 mice along with therapeutic cells followed by 
immunization with hMBP and PTx. The mice were observed and scored for EAE disease 
for 50 days. Recipients of the zeta-bearing therapeutic cells showed later onset of disease 
symptoms and milder course compared to the ones receiving MSCV control or zeta-
deficient RMTC. We have also tried to induce EAE by adoptive transfer of CD4+ cells 
from TTG mice and therapeutic cells followed by peptide immunization. MBP-DR2-ζ 
CTL completely blocked development of EAE disease, whereas mice that received 
MSCV CTL developed EAE within a week from injection. Since EAE is classically 
considered a CD4+ Th1-induced disease, the efficient elimination of these cells by the 
zeta-bearing therapeutic cells is an indication of their potency in blocking the disease. We 
also noticed that the mice that received MSCV control cells along with CD4+ target cells 
developed less severe signs of EAE than the mice that received unsorted target cells 
which might account for the role of CD8+ MBP-specific cells as “inducers” of EAE in 
this particular mouse model. Due to the lack of humanized MHC class II mice (Fug5) we 
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could not repeat these experiments, but this is a task we intend to pursue in the future. We 
also intend to test the ability of therapeutic cells to block disease induced by adoptive 
transfer of CD8+ cells from TCR/DR2/hCD4 transgenic mice. 
 The second approach for in vivo prevention of EAE disease involved the use of 
TCR/DR2 double transgenic mice as recipients of therapeutic cells. These mice received 
active peptide immunization and PTx two days after the transfer of RTMCs. Although 
these experiments need to be repeated, they yielded very encouraging results: mice that 
received zeta-bearing RMTC showed a delayed onset of disease, a milder course, and 
remission compared to the mice that received control CTL. The tailless chimeric 
receptor-transduced T-cells seemed to be efficient as well, though not in the same extent 
as the ones bearing the zeta signaling tail. Two more experiments validating these data 
are ongoing. 
 These studies are important for several reasons. The use of RMTC expressing 
humanized CR in humanized transgenic mice brings us one step closer to their use in 
treating multiple sclerosis in humans. Experimental therapies in humans are limited by 
both technical and ethical considerations whereas mice have similarities but are simpler 
to use as disease models. Conversely, although genetically similar, mice are not humans, 
and some therapeutic approaches that proved beneficial for them have not worked in 
humans or could even be harmful. HLA-transgenic mice are particularly useful in 
modeling autoimmune diseases associated with specific HLA alleles, such as MS. 
Although it is rather difficult to identify exactly the genes responsible for MS, due to the 
strong linkage disequilibrium, HLA class II has a clear contribution in predisposing to the 
development of disease (85). HLA is crucial as it governs T cell selection in the thymus 
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and antigen presentation in periphery. Upon binding of a TCR to a peptide antigen in the 
groove of MHC II, a cascade of signal transduction events ensues.   
CD4 costimulation may be required as a TCR interacts with MHC. The 
requirement in the humanized mouse model we have studied is less clear. The class II 
MHC used in this model is entirely human in sequence. Data from literature are 
extremely controversial on whether murine CD4 can bind human class II MHC. Some 
studies demonstrate that an entirely human MHC class II mouse cannot interact with 
mouse CD4 (96, 97). Therefore, in some humanized systems, a mixed, chimeric 
human/mouse class II molecule was engineered so that murine CD4 coreceptor could 
bind the β2 domain (also murine) of the transgenic HLA II (98). Another set of data 
seemingly contradicted this requirement. Altman et al. engineered humanized HLA-DR1 
transgenic mice and crossbred them with human CD4 transgenic mice (Hu-CD4) and 
tested the response of Hu-CD4 positive versus Hu-CD4 negative T-cells to influenza 
haemagglutinin (HA). T-cells proliferated strongly to this peptide regardless the CD4 
status (99). This suggests the possibility of interaction between human HLA class II and 
mouse CD4; however this was not formally proven. In our experience, using antigen-
specific T-cells from double transgenic or triple transgenic mice (including or lacking 
Hu-CD4) did not make a difference in the experimental results. 
Another issue regarding our system is the proliferative response of CD8+ antigen-
specific T-cells to peptide stimulation. EAE is classically considered a CD4 Th1 disease 
(100) and until recently the research was predominantly focused on this T cell phenotype. 
One study that used MOG35-55 as the immunodominant epitope showed equal 
proliferative potential of both CD4 and CD8 cells to this antigen and EAE induction by 
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adoptive transfer of CD8 antigen-specific cells (28). On the same note, the inflammatory 
infiltrate in the brain of the patients with MS incriminated both CD4 and CD8 T cell 
types along with B cells, and depletion of CD4 cells in MS patients only minimally 
decreased relapse rates (101). Invasion of the CNS after intravenous delivery of MBP-
activated, cytotoxic CD8 cells result in very severe ascending flaccid paralysis with high 
mortality (102). The aggressive and somewhat different manifestation of disease is a 
critical aspect for therapy as CD8-induced disease can be dampened by anti-IFN-γ 
antibodies (unlike the CD4-induced disease), while anti-TNF-α does not show any effect 
on the disease course. It is also noteworthy that perivascular inflammation leading to 
further demyelination in MS is composed mainly of CD8+ T-cells as these cells recognize 
endogenous antigens processed via the MHC class I pathway.  
CD8+ T-cells have been incriminated as culprits for MS. As a logical 
consequence, the humanized mice that we used for this project might actually be closer to 
the human disease than EAE mediated exclusively by CD4 T-cells, as the disease in this 
model might be caused by both CD4 and CD8 autoreactive T-cells. Since HLA-DR2 
mice bear human MHC class II, but not class I, a CD4 response to hMBP-stimulation is 
to be expected. All our experiments showed a proliferative ability of both CD4+ and 
CD8+ MBP-specific cells. Under the circumstances, we hypothesized that there are MHC 
class II-restricted CD8+ T-cells able to respond to peptide stimulation.  
If CD8+ T-cells play a prominent pathologic role in disease, they might become 
problematic for our therapeutic approach since we transduced the chimeric receptors into 
CD8+ T-cells that can only target and kill CD4+ antigen-specific cell lines, but not CD8+ 
antigen-specific cell lines. On the other hand, our RMTC are able to kill both cell types as 
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long as they are still naïve. Chimeric receptor-transduced CTL can still efficiently kill 
long-term activated antigen-specific CD4+ T-cells, whereas activated CD8+ MBP-specific 
cells become resistant to lysis. Under these circumstances, we attempted to prevent rather 
than treat disease by injecting therapeutic cells before EAE induction. This way we 
ensured very early cytolysis of the majority CD4 and CD8 naïve, antigen-specific cells. 
Indeed, when treated with zeta-bearing CR-transduced RMTC the mice developed EAE 
disease later than controls, had less severe disease, and developed a complete remission. 
A sensible explanation would be that the RMTC inhibited both CD4 and CD8 naïve, 
antigen-specific cells.       
Both in vitro and in vivo experiments using RMTC as a therapeutic tool did not 
show complete cytolysis or abrogate proliferation of target cells from TCR/DR2 mice. A 
rational question would be why residual MBP-specific cells could not get activated, 
proliferate, and induce disease. There are several possible explanations for this issue. One 
would be that the therapeutic cells are very potent in killing autoreactive T-cells and 
therefore, the low number of residual target cells would not be able to cause disease. This 
finding is true for both CD4+ and CD8+ population. A second reason refers to the 
relationship between CD4+ and CD8+ T-cells in the development of EAE disease. If CD4 
T-cells are effectively eliminated, CD8 T-cells would not be able to survive without the 
signals delivered by CD4 T helper cells. Therefore, although the chimeric receptor was 
transduced into CD8+ CTL that can only target and kill CD4 hMBP-specific cells, their 
disappearance would also impede survival of CD8+ hMBP-specific cells. 
 The in vivo efficacy of the ζ-deficient RMTC is still an open question. Removal 
of the cytoplasmic signaling tail impeded signal transduction and recognition of target T-
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cells by MBP-DR2-CTL. MBP-DR2 therapeutic cells cannot kill hMBP-specific cells. 
Likewise, they cannot inhibit proliferation of antigen-specific cells after peptide 
stimulation. The only option left that might explain is the conversion of autoreactive, Th1 
cells intoTh2 ones and secretion of anti-inflammatory cytokines (IL-4, 5, 13). This is one 
of the hypotheses that remain to be proven in the future.  
 A major limitation in the therapy of EAE is the phenomenon of epitope spread. 
The disease in primarily induced by a particular antigenic peptide that activates T-cells 
but due to local inflammation and damage, the T-cell response will extend to other 
epitopes within the same antigenic protein or different proteins  (103). Naïve T-cells can 
penetrate the inflamed CNS without the need of peripheral activation (104). Dendritic 
cells in the CNS will then activate these naïve T-cells, thus initiating epitope spread 
(105). This phenomenon occurs after the peak of acute disease, around day 16 after 
immunization with a specific peptide and it is inhibited by treatment with IFN-β (106). 
HLA-DR15/MBP85-99 humanized transgenic mice were shown to undergo epitope 
spread to other HLA-DR15-restricted MBP epitopes. We do not know if this would also 
happen in our humanized system. Previous reports from our lab using RMTC specific for 
MBP89-101 reactive T-cells after epitope spread showed symptomatic improvement of 
EAE-induced mice. In addition lymphocytes from the mice showed decreased 
proliferation not only to MBP89-101, but also to two PLP epitopes, 139-151 and 178-
191, that are important in epitope spread (58). Although these constitute encouraging 
data, we can not assume that humanized chimeric receptor-transduced therapeutic cells 
would also block epitope spread in our humanized system and this is an important 
question to be addressed in the future. 
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 The ultimate goal of this entire project using T-cells transduced with chimeric 
receptors for the therapy of MS in a humanized mouse model is to eventually use this 
approach in human clinical trials. Several adjustments should be made for the chimeric 
receptors to meet the safety requirements of such trials. The GFP gene is suitable for 
experiments in mice but it induces an immune response in humans (107). Therefore, this 
gene should be removed as the RMTC can be easily detected and quantified by staining 
with the DR2 antibody. Moreover, since there is very little data about the side-effects of 
RMTC presenting an autoantigen, a suicide mechanism would be beneficial so that their 
prompt elimination becomes readily possible. One way to do this is insertion of herpes 
simplex virus thymidine kinase gene (hsvTK) into the transduced construct.  This 
converts the dideoxynucleoside prodrug gancyclovir into its phosphorylated form, thus 
terminating the DNA chain and leading to cell death (108).  
 In this project we only tested the ability of CD8+ T-cells transduced with CRs to 
prevent or treat EAE in the humanized system. There are several other variations to this 
theme. One of them is transduction of CRs into Th2 lymphocytes or regulatory 
CD4+CD25+ T-cells. These therapeutic cells will not directly kill autoreactive, peptide-
specific cells, but rather act through different mechanisms, such as anti-inflammatory 
cytokines. In this manner they may be more potent than the CD8+ RMTC cells in settings 
where significant epitope spreading has already taken place.  The field is still wide open 
for the use of CRs and other, more “classical”, non antigen-specific approach for the fight 
for the cure of this disease. 
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